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ABSTRACT 
Over the past several years whole exome sequencing (WES) by high-throughput sequencing of 
target-enriched genomic DNA has become both technically feasible and financially practical as a 
means of studying Mendelian disorders. It is also entering the clinical realm as a powerful 
diagnostic tool for cases that have eluded answers and a cost effective one for cases with a 
suspected genetically heterogeneous disorder or set of differentials. This thesis examines the 
strategies for use and impact of such a technology in both the research and clinical setting. It 
presents an analysis of two cases in which WES was used to determine the causative mutation in 
the phenotype of an unknown/undiagnosed genetic disorder. The results demonstrate the 
strengths and limitations of variant filtering strategies, the need for co-segregating familial 
samples when possible, the value of a detailed phenotypic picture and family history, and value 
of functional studies in confirming the pathogenicity of candidate variants. In the first case 
report, WES succeeded in narrowing the candidate list to a manageable size for two sibs affected 
in the neonatal period with seizures, encephalopathy, and thrombocytopenia, and who died at a 
few months of age. Sequencing data on the parents and unaffected sibling is needed to elucidate 
the pathogenic mutations. In the second case report, WES detected a strong candidate mutation 
in NDUFAF6, a complex 1 assembly factor. Given the patient’s presentation with multi-organ 
dysfunction, dramatic skeletal myopathy, and degenerative course suggestive of a mitochondrial 
disorder, complex 1 deficiency was suspected but Sanger sequencing failed to confirm the 
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mutation. This thesis also examined the ethical and practical considerations involved in 
incorporating WES into clinical practice and its impact on public health, namely improved 
treatment options for patients and an improved knowledge of the relationship between genetics 
and disease phenotypes.  
 
 
 v 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ....................................................................................................... XI 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 THE GENOME .................................................................................................... 2 
1.2 THE DEVELOPMENT OF WES ...................................................................... 2 
1.3 IDENTIFYING DISEASE GENES.................................................................... 3 
1.3.1 DNA Capture and Enrichment Technology .................................................. 4 
1.3.1.1 Nimblegen .............................................................................................. 4 
1.3.1.2 Agilent .................................................................................................... 4 
1.3.1.3 Illumina .................................................................................................. 5 
1.3.1.4 Broad observations ............................................................................... 5 
1.3.2 Sequencing Platforms ...................................................................................... 6 
1.3.2.1 Applied Biosystems7 .............................................................................. 6
1.3.2.2 Illumina8 ................................................................................................. 7
1.3.2.3 IonTorrentTM 9-11 ................................................................................... 7
1.3.3 Data Analysis Strategies .................................................................................. 8 
1.4 COMPARISON TO OTHER TESTS .............................................................. 12 
1.5 DRAWBACKS TO WES .................................................................................. 14 
2.0 CASE SUMMARY 1 .................................................................................................. 16 
vi 
2.1.            BABY AA........................................................................................................... 16 
2.2        BABY MM ......................................................................................................... 17 
2.3 CASE SUMMARY 2 ......................................................................................... 18 
3.0 METHODS ................................................................................................................. 19 
3.1.1 DNA capture and amplification ................................................................... 19 
3.1.2 Sequence by ligation ...................................................................................... 20 
3.1.3 Initial analysis ................................................................................................ 21 
3.1.3.1 Case 1 ................................................................................................... 21 
3.1.3.2 Case 2 ................................................................................................... 21 
3.1.4 Variant analysis ............................................................................................. 22 
3.1.4.1 Case 1 ................................................................................................... 22 
3.1.4.2 Case 2 ................................................................................................... 23 
4.0 RESULTS ................................................................................................................... 25 
4.1 CASE 1 ................................................................................................................ 25 
4.2 CASE 2 ................................................................................................................ 27 
4.2.1 Round 1 Analysis ........................................................................................... 27 
4.2.2 Round 2 Analysis ........................................................................................... 28 
5.0 DISCUSSION ............................................................................................................. 32 
5.1 CASE 1 ................................................................................................................ 32 
5.2 DIFFERENTIAL DIAGNOSES FOR CASE 2 .............................................. 33 
6.0 SIGNIFICANCE ........................................................................................................ 35 
6.1 IMPACT ON GENETIC COUNSELING ....................................................... 35 
6.1.1 Ethical Issues .................................................................................................. 35 
vii 
6.1.1.1 Informed Consent ............................................................................... 36 
6.1.1.2 Return of Results ................................................................................. 37 
6.1.1.3 Pediatric versus Adult WES............................................................... 38 
6.1.2 Diagnostic odysseys and negative results ..................................................... 38 
6.2 IMPROVED THERAPEUTIC OPTIONS ...................................................... 39 
6.3 LIMITATIONS .................................................................................................. 41 
6.4 FUTURE DIRECTIONS................................................................................... 45 
7.0 CONCLUSION ........................................................................................................... 46 
APPENDIX A: Supplementary Tables ..................................................................................... 47 
APPENDIX B: Consent Forms .................................................................................................. 55 
APPENDIX C: Comparison of Commercially Available WES .............................................. 72 
BIBLIOGRAPHY ....................................................................................................................... 76 
viii 
 LIST OF TABLES 
Table 1 Case 1 Homozygous Candidate Mutations ...................................................................... 26 
Table 2 Final Candidate Gene List, all homozygous mutations ................................................... 29 
Table 3 Case 1 Compound Heterozygous Candidate Mutations .................................................. 47 
Table 4 Case 2 Round 1 Compound Heterozygous Candidate Mutations.................................... 50 
Table 5 Case 2 Round 1 Insertion Candidates .............................................................................. 51 
Table 6 Case 2 Round 1 Exonic Deletions ................................................................................... 52 
Table 7 Case 2 Round 2 Compound Heterozygous Candidates ................................................... 52 
Table 8 Comparison of Commercially Available WES by Laboratory ........................................ 72 
 ix 
LIST OF FIGURES 
Figure 1 Sample pipeline for variant analysis ................................................................................. 9 
Figure 2. MRI of MM, showing multicystic encephalomalacia ................................................... 18 
 x 
ACKNOWLEDGEMENTS 
It takes a village to raise a child, and similarly this project is the culmination of the efforts and 
attentions of many people beyond myself. Naturally, I would like to thank Dr. Jerry Vockley for 
allowing me to be a part of such a fascinating project at such a crucial stage in the life of this 
technology. Dr. Lina Gonzalez, for working side-by-side with me on these patients and without 
whose knowledge of resources none of the analysis would have been possible. Dr. You Li of Dr. 
Cynthia Lo’s lab and Rahil of the Greater Pittsburgh Cytogenetics Lab for getting what must 
have been extremely nasty raw data into a legible, analyzable form. Importantly, I would like to 
acknowledge the patients and their families presented in this thesis, for putting their trust in us to 
find them the answers they so dearly want in the face and aftermath of such suffering as a result 
of something as deceptively simple as a mistake in a DNA sequence. I would like to thank Robin 
Grubs and Betsy Gettig for their faith that I would be a worthwhile contributor to, and participant 
in, the University of Pittsburgh’s Genetic Counseling Program. I truly believe that I found my 
way to the place where I needed to be at the time that I needed to be here and I cannot imagine 
any other program giving me what I found in Pittsburgh. On that note, I would like to thank 
Professor Murray Krantz for just happening to mention genetic counseling as a career option in 
passing “that one day” in class. I would also like to thank the lovely ladies of “the Herd” for 
sharing these two wonderful, crazy years with me. I could not ask for a better group of girls in 
the class of 2013. Finally, and most importantly, I would like to thank my Mom and Dad for the 
 xi 
love, care, and support they have provided me with throughout my life – and the good genes they 
gave me! I wouldn’t be who I am today without such amazing parents like you and words can’t 
express how grateful I am for all that you have done and continue to do for me, including 
knowing when to take a leap of faith and let me stand of my own two feet. I love you both so 
much.   
 
 
 xii 
1.0  INTRODUCTION 
In 2001, after 13 years of effort, the first human genome was sequenced by the Human Genome 
Project at an estimated cost of $2.7 billion.1 Since that time, the development of massively 
parallel pryrosequencing platforms has allowed the adoption of high-throughput genomic 
analysis known as next-generation sequencing, NGS, increasing the capacity to generate and 
analyze larger quantities of genotypic and phenotypic information than ever before. Over time, 
improvements to technology have also lowered the cost and improved the time required to 
sequence a human exome. Though until recently confined to a research setting, whole-exome 
sequencing (WES) is now available on a clinical basis through laboratories such as Baylor 
Genetics, Ambry Genetics, and GeneDx. WES has so far been shown to be a powerful tool in 
elucidating the causes behind many Mendelian diseases and in the clinical setting promises to 
provide a more effective method of providing patients with answers. Improved knowledge of 
pathogenic variants and their disease associations can allow one to prepare for, avoid, or treat the 
negative impacts that they can have on health, lifespan, and offspring. As with any new 
technology there are often many aspects to consider and challenges to overcome in its use. This 
project aimed to explore these issues, including an evaluation of the technology itself, its utility 
in discovering candidate genes for novel genetic syndromes and the data analysis process, and its 
impact on the field of genetics using two case studies of individuals affected by an unknown 
disorder. 
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1.1 THE GENOME 
The human genome is composed of roughly 3 billion nucleotide base pairs arranged into 
approximately 30,000 genes. Each gene contains both protein-coding and non-coding regions. 
Coding regions (exons) contain information for the construction of the amino-acid sequence of 
the protein product and structural or regulatory RNA species. Non-coding regions include introns 
and the 3’- and 5’ regions of each gene; their function is unknown at this time. Most variation 
between humans occurs in the non-coding DNA regions and in degenerate positions in amino 
acid codons that do not change the intended identity of the amino acid. Humans vary on average 
ever 1 out of 100 nucleotides and most of these variations occur frequently in the population with 
little or no effect on protein function. As such, they are called polymorphisms. Mutations in the 
genetic sequence are more likely to have detrimental effects if they result in a shift of the reading 
frame, non-synonymous substitution of one amino acid for another (particularly amino acids 
with vastly different chemical properties), insertion of a premature stop codon resulting in a 
truncation of the protein product, or loss of a stop codon. Though protein-coding genes comprise 
only about 1% of the genome, they harbor about 85% of the mutations with large effects on 
disease-related traits.1  
1.2 THE DEVELOPMENT OF WES 
After the completion of the Human Genome project it was still too expensive to sequence large 
numbers of human genomes. Researchers instead demonstrated that it was possible to capture 
and sequence the protein-coding exons from human genomes, leading then to the analysis of the 
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complete set of exons in the genome, labeled the exome. By 2009 researchers had used WES to 
discover the genetic basis for Bartter syndrome, Miller syndrome, and Kabuki syndrome.2. In 
2011, exome sequencing was used to determine the basis for a previously undescribed and 
idiopathic disorder later named Ogden syndrome, which was shown to be located on the X 
chromosome and result from a defect in the amino-terminal acetylation of proteins. 3 Since 2009, 
more than 20 causative genes have been identified and the number is only expected to grow 
exponentially.1  
1.3 IDENTIFYING DISEASE GENES 
Until the advent of WES, most studies aiming to identify new genetic causes of disease used 
linkage analysis (positional cloning). These usually identified a genomic interval spanning 0.5-
10 cM which could contain up to 300 genes. By 2009 that strategy identified less than 2000 
genes responsible for less than 4000 diseases, with some genes being linked to multiple 
conditions.4 We know also that genome of the human species as a whole is subject to numerous 
new pathogenic mutations each year. The number of  known mutations in the human nuclear 
genes that either cause or are associated with heritable diseases exceeds 100,000 in more than 
3700 different genes.1 Even so, a large number of genes responsible for the approximately 7000 
Mendelian diseases still remain unidentified and there are undoubtedly more Mendelian 
disorders that have not yet been named or discovered. When it comes to the process of using 
WES to discover candidate genes for such disorders, there are a number of factors to take into 
consideration.  
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1.3.1 DNA Capture and Enrichment Technology 
The three major next-generation sequencing platforms are Illumina, Nimblegen, and Agilent. 
Each of these platforms is compatible with the major commercial options for the first step of 
WES, which is enriching the exonic sequences. The sequencing platform kits tend to contain 
exons from the consensus coding sequence project, which currently comprises 176,266 exons 
from 18,409 genes, as well as additional sequences. 4 Each company also has developed its own 
exome enrichment platform (Agilent’s SureSelect Human All Exon 50Mb, Roche/Nimblegen’s 
SeqCap EZ Exome Library v.2.0, and Illumina’s TruSeq Exome Enrichment), which differ in 
design and experimental parameters that can affect variant discovery. Clark et al. 2011 
performed a systematic analysis of these differences. 5 
1.3.1.1 Nimblegen 
Uses DNA for capture of targeted genomic sequences. The platform contains overlapping baits 
that cover target bases multiple times, resulting in the highest density coverage of the three 
platforms. It covers a greater portion of miRNAs compared to other enrichment platforms. 
1.3.1.2 Agilent 
Uses RNA for capture of targeted genomic sequences, where baits reside immediately adjacent 
to each other across target exon intervals. It provides better coverage of genes in the Ensembl 
database. 
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1.3.1.3 Illumina 
Uses DNA for capture of targeted genomic sequences and relies on paired-end reads to extend 
outside bait sequences and fill gaps. The majority of targets unique to this platform cover 
untranslated regions (UTRs).  
1.3.1.4 Broad observations 
Each platform contains 4.4-28Mb of unique target region. Nimblegen and Agilent share more 
with each other (38.8Mb) than either does with Illumina (30.3 Mb and 33.3 Mb respectively). 
29.45Mb were found to be targeted by all three platforms. Coverage of mRNA coding exons in 
both RefSeq and Ensemble were similar between all platforms. Nimblegen enriched a higher 
percentage of targeted bases, which Illumina and Agilent enriched a higher total number of bases 
at higher read counts. A higher density design, targeting a smaller genomic interval, results in 
higher efficiency. Lower density designs required substantially larger amounts of sequencing, as 
efficient baits became saturated at 40M (Nimblegen) versus 50M (Agilent) and 60M (Illumina) 
reads. The percentage of off-target enrichments correlated strongly with this trend.  
A potential source of inefficiency comes from areas with high GC or AT content, as low 
coverage in these areas has been observed 6. All three platforms showed a sharp drop in read 
depth as GC content increased from 60% to 80%. As GC content dropped from 40% to 20%, 
Illumina and Nimblegen diminished with lower read depth over those targets, where the Agilent 
platform displayed only a slight reduction in read depth. This was felt to be due to its lower 
number of PCR cycles, longer baits, and/or the use of RNA probes.  
In the detection of singly nucleotide variants (SNVs), concordance rates for a normalized 
80M read exome data set compared to the SNP Chip were 99.3% for Agilent, 99.5% for 
Nimblegen, and 99.2% for Illumina. Allelic balance (AB) was calculated by determining the 
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ratio of reference base calls over the total number of calls at every SNV with a quality score of 
30 or better (99.9% probability of an accurate call). For Agilent, AB=0.55, and 0.53 for both 
Nimblegen and Illumina. Therefore the reference biases were not strong, but explained some of 
the discordance with the SNP Chip data set. No significant different in the ratio of heterozygous 
to homozygous variants were observed between platforms. In shared regions, Nimblegen 
captured the most SNVs with the lowest number of reads, followed by Agilent and then Illumina. 
This demonstrates a correlation between bait density and sensitivity to SNV detection, and 
Nimblegen was also more effective at detecting SNVs in low-complexity, hard-to-target regions. 
Agilent detected unique SNVs most often in introns, as its baits sometimes extend farther outside 
of exon targets than the other platforms.   
Coverage of regions containing insertions and deletions (indels) largely match coverage 
in other targeted regions. Small insertions and deletions ranging from -84bp to +18 bp were 
detected at a frequency of 12.5-14.5% that of SNVs. At lower read counts, more indels were 
detected after Agilent enrichment than Illumina. Past 50M reads, the reverse was true. In shared 
and RefSeq regions, Nimblegen had the highest sensitivity to detecting indels at lower read 
counts, while Agilent enrichment led to the largest number of detected indels at every read count 
in Ensembl CDS exons.  
1.3.2 Sequencing Platforms 
1.3.2.1 Applied Biosystems7 
Applied BiosystemsTM  by Life Technologies offers the SOLiD sequencing platform, which 
stands for Sequencing by Oligonucleotide Ligation and Detection. Four fluorescently labeled di-
base probes compete for ligation to the sequencing primer. Specificity for the di-base probe is 
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done by interrogating every first and second base in each ligation reaction, and the eventual read 
length is determined over multiple rounds of ligation, detection, and cleavage. Following a series 
of these ligation cycles, the extension product is removed and the template is reset with a primer 
complementary to the n-1 position for a second round of ligation cycles. Five rounds of primer 
reset are completed for each sequence tag. This allows nearly every base to be queried in two 
different ligation reactions by two different primers, improving the accuracy of nucleotide base 
calls. Variations from the reference sequence display as a fluorescent color change; sequencing 
errors would therefore show as one change while accurate calls would show two. 
1.3.2.2 Illumina8  
Illumina’s sequencing platform uses sequencing by synthesis (SBS) technology to generate 
exome data. The technology is able to detect single bases as they are added to DNA strands using 
a reversible terminator-based method. The fluorescent terminator is imaged as 
deoxyribonucleotide triphosphate (dNTP) is added, and then cleaved so that the next base can be 
added and imaged. Incorporation bias is minimized by competition, as all four reversible 
terminator-bound dNTPs are present during each sequencing cycle. SBS supports both single 
read and paired end libraries. The platform combines short-insert paired-end capabilities as well 
as long-insert paired-end reads to fully characterize the genome being sequenced.  
1.3.2.3 IonTorrentTM 9-11 
Ion Torrent is a long-read high-density semiconductor sequencing platform developed by Roche 
454 Life Sciences in partnership with DNA Electronics. It is based on the detection of hydrogen 
ions that are released during the polymerization of DNA and represents another method of SBS. 
As the dNTP is incorporated into the DNA strand complementary to the template, the release of 
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a hydrogen ion triggers an ISFET ion sensor and records that a reaction has occurred. In this 
sequencing technology, unlike the others, no modified nucleotides or optics are used. Instead, 
only a single species of dNTP is used at a time compared to the simultaneous presence of all four 
dNTPs in other platforms. If the dNTP is not complementary to the template nucleotide, there is 
no reaction. The per base accuracy was 99.6% based on 50 base reads with 100Mb per run, with 
read lengths of 100 base pairs.  One of the strengths of this technology is a rapid sequencing 
speed and low cost possible by avoiding the modified nucleotides and optical measurements. 
With this system it is difficult to enumerate long repeats, as multiple ions will be released as 
multiple nucleotides are incorporated and it is difficult to distinguish signals from a high repeat 
sequence from ones of a similar but different number (such as 7 repeats instead of 9). It also has 
a shorter read length and lower throughput than other sequencing technologies, though 
increasing the density of the chip might change this.   
1.3.3 Data Analysis Strategies 
The first major hurdle to overcome when analyzing a set of exome sequencing data is the sheer 
number of variants that are present compared to the reference sequences. Based on the literature, 
a researcher can expect to be confronted with anywhere from 20-30,000 variants in a single 
exome sequence. Of these, approximately 10,000 will be predicted to result in nonsynonymous 
amino acid substitutions, splice-site alterations, insertions, or deletions.4 Filtering these results 
further requires a set of assumptions about which variants are more likely to be deleterious.  
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 Figure 1 Sample pipeline for variant analysis 
Variants reported to be common in the general population are not likely to be responsible 
for Mendelian disease. Such variants can be found in databases such as dpSNP, the 1000 
Genome Project, and in-house exome databases. The caveat for using these databases is that 
there is a change that information on certain variants is mislabeled, though databases make 
efforts to correct such errors when they encounter them. For example, of the more than 17 
million SNPs in the human genome documented in dbSNP, the false-positive rate is estimated at 
15-17% 12. Computational algorithms are available online that can predict the pathogenicity of 
variants and can therefore allow variants that are predicted to be benign to be removed. Two 
examples of these databases are SIFT and PolyPhen. However, computational algorithms in 
general have been shown to have high false-positive and false-negative rates, likely at least 20% 
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for WES data.4 Therefore, this kind of filtering is more useful once other filters have already 
been applied to narrow the list of candidate genes to a manageable size. The NHLBI Exome 
Variant Server, composed of the data from the NHLBI Grand Opportunity Exome Sequencing 
Project, allows researchers to check variants that they have found against a database of 6503 
exomes in the current version. The goal of the ESP data set is to the frequency of counts of 
specific variants without regard to phenotype. The data set was selected to contain controls, as 
well as extremes of specific traits (LDL levels and blood pressure) and specific diseases (early-
onset myocardial infarction, early-onset stroke, and lung disease). Once variants of interest have 
been identified, it can also be useful to determine whether the gene is one that is conserved 
across evolution, and therefore a more functionally important gene, using the UCSC Genome 
Browser. The mutation(s) of greatest interest can then be confirmed using Sanger sequencing, 
particularly if the read coverage is relatively low, and, if possible, functional studies can be 
performed on tissue samples to confirm the physiologic effects of the mutation, such as reduced 
enzyme activity. 
In the event that multiple unrelated individuals with the same phenotype are available for 
sequencing, comparison of their common variants can be extremely useful as a filter. The 
assumption is that sequence variants unrelated to the disease of interest will be randomly 
distributed in the exome; thus the likelihood of these individuals sharing the same variants by 
random chance becomes extremely low. This strategy cannot be used in a blanket approach, 
however, as it neglects the possibility of genetic heterogeneity. When determining the genetic 
basis of Kabuki syndrome in 10 unrelated individuals, only one gene was found to have at least 1 
non-synonymous/splice site/indel mutation in every individual. The gene, MUC16, codes for a 
 10 
protein that provides a lubricating barrier against particles at mucosal surfaces and was clearly a 
false-positive result.13.  
Whole-exome sequencing does not negate the need to consider the suspected mode of 
inheritance in a patient, especially when parent or other family samples are available for 
comparison. If there is enough medical history data to theorize a mode of inheritance, or an 
etiological diagnosis can be made from the phenotype of the patient, this can provide another 
filter by which to narrow candidate genes. Autosomal recessive conditions would manifest as a 
set of homozygous or compound heterozygous mutations in the proband and each parent would 
be expected to be a carrier of one or the other mutation. Autosomal dominant conditions would 
be present in a heterozygous form in the proband and the mutation may or may not be carried by 
the parent. Additional considerations for dominant conditions include reduced penetrance and 
variable expressivity, making a detailed examination of the parents for their offspring’s traits 
extremely useful, if it is possible to gather such information. If an X-linked condition is 
suspected, the mutation would be expected to be present hemizygously in the proband and in a 
heterozygous state in the proband’s mother. Lack of presence in the mother should not be 
immediate cause for discarding of the variant, as some of these conditions have high rates of de-
novo cases. In Duchenne Muscular Dystrophy, a woman has only a 2/3 chance to be a carrier 
when she has a single affected son.  
There is research to suggest that the role of de novo mutations in certain situations is 
underappreciated. Often medical genetics professionals encounter isolated cases of mental 
retardation, multiple congenital anomalies, or other diseases. Unless adiagnosis can be made, the 
underlying basis of the condition is unclear and can possible be autosomal recessive, 
multifactorial, due to environmental factors, oligogenic, or the result of a spontaneous mutation. 
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The per-generation mutation rate has been estimated at 7.6x109 – 2.2x108, roughly 1/100 million 
positions in the haploid genome. This would translate into a rate of 0.86 amino-acid-altering de 
novo mutations per person.14 In situations such as intellectual disability where there is such 
genetic heterogeneity, analysis strategies can use parent-child trios to examine potentially 
pathogenic de novo mutations. In one such study, WES was obtained on 10 trios after ruling out 
CNVs by microarray. Exclusion of common, predicted non-pathogenic, and non-de novo 
mutations led to the identification of convincing candidate mutations in 7 of the 10 patients.15   
1.4 COMPARISON TO OTHER TESTS 
Previously, physicians were restricted to single-gene diagnostic odysseys or multi-gene panels, 
which could in some cases cost more than $100,000 and stretch over several years or many more 
2, depending on if a causative mutation was ever identified. Exome, or even whole-genome 
sequencing, can examine all of the genes in the genome at various levels for a fraction of the 
price.  
Compared to WGS, single-nucleotide variants found WES average greater Phred-based 
quality scores. Phred scores were originally developed by the computer program Phred to assist 
in the automation of DNA sequencing in the Human Genome Project. They are a measure of the 
probability of a variant base call being incorrect. The higher the quality score, the lower the 
probability of an incorrect call.16 There are some regions (and therefore variants) missed by a 
typical WGS but observed in WES due to the higher coverage achieved by the target-enriched 
sequencing of specific regions. Similarly, there are some targeted regions and variants missed by 
WES that are detectable by WGS5, and WGS can, by using a paired-end approach, detect large 
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structural variations such as insertions, deletions, inversions, and translocations.1 However, to 
detect those one much be prepared to receive variant data on many genomic regions in which 
there is little evidence to be concerned about disease loci and, if insertions and deletions are the 
main variant of interest, high-coverage array CGH can perform the same function for a lower 
price and less extraneous information. Repetitive regions, exonic and other, are difficult to align 
in either case and can result in either missed variants or an excess of variant calls, and WGS is 
not immune to the drawbacks of WES including variation in coverage and efficiency of 
sequencing across the genome.1 Though in the future WGS is predicted to be more economical 
than WES as it bypasses the need for the capture process, the amount of data generated by WGS 
is 100x more than the already overwhelming amount of data obtained through WES that is 
proving a challenge for data storage, bioinformatics filtering capabilities, and hardware and 
software for analysis.1 Ultimately, unless analysis is to be focused on non-coding regions or 
structural variation, WES provides most of the benefits of WGS at a lower cost.  
At this time, WES is not efficient as a first-line approach, and this is recognized by the 
American College of Medical Genetics and Genomics. Currently, it is recommended that WES 
be considered in the clinical diagnostic setting of an affected individual in one of three situations: 
if the phenotype or family history suggests a genetic cause, but the phenotype does not 
correspond to a specific disorder for which a targeted genetic test is clinically available; if the 
patient presents with a defined disorder that is known to have a high degree of genetic 
heterogeneity and thus WES is more practical and cost-effective; or, if the patient presents with a 
likely genetic disorder but specific genetics tests for the phenotype have failed to yield a 
diagnosis.17 It is possible to perform WES prenatally, in the event that a fetus with a likely 
genetic disorder has failed to be diagnosed by other means, but ACMG counsels caution as WES 
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has several limitations in this setting, including a long turn-around time, and significantly higher 
rates of false-positives, false-negatives, and uncertain variants than seen with other prenatal 
technologies such as array CGH.17 If the parents have decided to carry the pregnancy to term, it 
may be just as timely to undergo sequencing neonatally. Current research is looking at new WGS 
protocols that use automated bioinformatics analysis to develop a differential diagnosis within 50 
hours18 for use in neonatal intensive care units, as more than 20% of infant deaths are caused by 
congenital malformations, deformations, and chromosomal anomalies.18 Hopefully, such an 
approach will continue to be refined and prove clinically useful at providing faster diagnoses and 
targeted treatment options families dealing with traumatic experience of having new baby with 
health issues.   
1.5 DRAWBACKS TO WES 
It is possible that mutations could be located in exons that are poorly covered by current 
targeting technologies and thus the candidate gene could falsely be removed from consideration. 
Currently, reasonable coverage can be achieved for approximately 90% of the sequenced 
exome.4. It has been found that 5-50% of RefSeq exons (approximately 3% of RefSeq coding 
exons) have less than 5x coverage in current commercial capture kits 1. In addition, the ability to 
interpret results is also only as good as our current knowledge of the genes, their functions, 
expression, and possibly associated conditions.  
Relevant variants might be predicted to be deleterious by algorithms such as SIFT or 
PolyPhen, but if little or nothing is known about the gene that they are located in such variants 
might have been falsely removed from consideration at earlier filtering stages. A relevant 
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mutation might also be falsely removed for not falling into the typical nonsynonymous/splice 
site/indel categories. A mutation that induces exon skipping can cause Mendelian disease, such 
as the silent mutation c.6354C>T in exon 51 of the fibrillin-1 gene in Marfan syndrome 19, and 
yet would not be detectable based on current filtering strategies.  
Though most point mutation in inherited diseases so far have been located in or near 
exons, mutations in distant enhancers and regulatory elements have been implicated in hereditary 
conditions and would not typically be detectable using current enrichment strategies. Point 
mutations in the ZRS region, the long-range limb-specific cis-regulator of the sonic hedgehog 
(SHH) gene, were shown to cause pre-axial polydactyly in cat models.20 As mentioned above in 
the case of Kabuki syndrome, genetically heterogeneous disorders can be missed in study groups 
of unrelated individuals, as individual patients could have varying gene involvement.  
Researchers and clinicians should take care when considering dominant conditions, as 
potentially relevant mutations may be falsely discarded if they are present in an unaffected 
parent, even though reduced penetrance is a common feature of many such disorders.  
There are logistical drawbacks to WES as well. The comprehensive nature of WES demands a 
longer turnaround time compared to traditional singe-gene tests or multi-gene panel. Labs 
currently offering clinical WES quote turnaround times of anywhere from 15-28 weeks, which 
can be an agonizing wait for patients who want to discover the cause of their condition, receive a 
diagnosis, and make use of available treatment or management guidelines. Currently next-
generation technologies also have difficulty accurately calling insertions, deletions, tri-nucleotide 
repeats, and copy number variations, so a second testing method is usually required to identify 
these with a good degree of confidence, adding to the cost.21 Whole-exome sequencing currently 
costs approximately $8,000 and has varying levels of insurance coverage.  
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2.0 CASE SUMMARY 1 
Whole-exome sequencing was performed on the five members of family A. The mother and 
father were healthy individuals who were not consanguineous but were both from Iraq. They had 
one son who was unaffected. The mother was noted to have low levels of protein Z on a blood 
test dated February 25, 2011.A blood sample taken in April of 2012 showed abnormal levels of 
protein Z (0.68, reference range 0.70-2.61) and factor X (120, reference range 0.60-140). 
2.1 BABY AA 
Baby female AA was born in 2009 at 31 weeks gestation by Cesarean section due to 
decelerations. The pregnancy was significant for gestational diabetes which was well-controlled, 
with insulin therapy beginning at 28 weeks. Ultrasounds revealed a small head circumference as 
well as a suspected head mass. The birth weight was 1357 g with APGAR scores of 7 and 9. 
There was thick meconium with a true knot in the placenta and a single nuchal cord. Though 
serum cytomegalovirus IgG was positive, there were no overt maternal signs of a CMV 
infection; parvovirus and toxoplasmosis testing were negative. Baby AA demonstrated low 
platelets after birth and was worked up for Neonatal Alloimmune Thrombocytopenia by NICU 
staff. AA had microcephaly and developed SIADH (syndrome of inappropriate antidiuretic 
hormone secretion) at day of life 10. A brain MRI showed multiple areas of intracranial 
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hemorrhage in the white matter, basal ganglia, and thalamus. The hemorrhage was from both old 
and new bleeds. TORCH testing was negative. Testing on factor XIII, factor VIII, the 
thrombophilic risk panel, protein Z, and the extended LAC panel was negative. AA died at a few 
months of life.   
2.2 BABY MM 
Baby female MM was born in 2010 at approximately 38 weeks gestation by (C-section vs. 
NSVD). The pregnancy was again significant for gestational diabetes. Birth length was in the 
10th percentile, birth weight was in the 3rd percentile, and head circumference was 10th percentile. 
Her status was normal until day of life 9 when she began to deteriorate, showing hypothermia, 
hypotonia, foot drop, and respiratory failure requiring intubation. MM was placed on a 
mechanical ventilator as well as total parenteral nutrition. Numerous raised blancheable pink 
papules were noted on her face and trunk. Pathology was consistent with PLEVA. She developed 
thrombocytopenia, anemia, seizures, and cerebral hemorrhage, and passed away at four months 
of age. The autopsy report revealed hepatomegaly with cholestasis, hemosiderosis, and fibrosis; 
congestive splenomegaly; mild bronchopulmonary dysplasia; and bilateral serosanguineous 
hydrothorax. MRI revealed global multicystic encephalopathy due to a prolonged continuous 
series of small discrete infarcts affecting the cortex, subcortical gray matter, and hindbrain 
structures. There appeared to be a relationship between small vessel vasculopathy and the 
infarcts. The vasculopathy was unusual with intimal foam cell accumulation, and interestingly 
limited to the central nervous system, appearing to even spare the spinal cord. A primary cause 
of the vasculopathy could not be determined and prior coagulopathy evaluation was normal.  
 17 
 Figure 2. MRI of MM, showing multicystic encephalomalacia 
2.3 CASE SUMMARY 2 
Patient TW was a Caucasian woman in her 40’s affected with multi-organ dysfunction, normal 
intelligence, and dramatic skeletal myopathy with normal heart function. Onset of muscle 
weakness was noted around in her early teens accompanied by episodes of mild hypoglycemia 
and hyperammonemia during periods of intercurrent illness. Over the years the disease has 
followed a neurodegenerative course. Extensive genetic testing for mitochondrial disease 
performed at another institution over many years was normal, including most recently Baylor’s 
MItome400, a targeted gene sequencing panel for >400 nuclear encoded mitochondrial genes. A 
previous muscle biopsy for mitochondrial respiratory chain enzyme testing obtained only fibrotic 
tissue, and the analysis could not be performed. TW was adopted and there is no information 
about her biological family. 
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3.0  METHODS 
WES was first undertaken on fibroblasts obtained post-mortem from Baby A, and on 20 ml 
whole-blood in two EDTA tubes from Baby M and TW. Whole blood was frozen immediately 
and shipped on dry ice to the Greater Pittsburgh Cytogenetics Laboratory (GPCL). Following 
sequencing and analysis of variants found in Baby A and Baby M, sequencing was performed on 
20ml whole blood from their mother, father, and unaffected brother. WES was undertaken on 
DNA isolated from whole blood and initial analysis was performed by GPCL and Dr. Cecilia 
Lo’s lab depending on the sample. Some samples were sequenced using either the 
SOLiDTM5500xl system at GPCL or Illumina HiSeq2000 at the Beijing Genome Institute, taking 
advantage of a discount provided to Dr. Lo.   
3.1 DNA CAPTURE AND AMPLIFICATION 
DNA capture and amplification from WBC genomic DNA was performed using the 
SureSelectTM Enrichment System. The 50 Mb SureSelect Human All Exon Kit is designed to 
target all human exons in a single tube, covering 99% of CCDS regions 
(http://www.ncbi.nlm.gov/projects/CCDS/CcdsBrowse.cgi), with additional Ensembl, Genebank, 
and RefSeq content. Genomic DNA was fragmented by sonication using CovarisTM S2 (Covaris 
Inc, MA) and sequencing primers were ligated. SureSelectTM baits, composed of biotinylated 
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RNA were hybridized to fragmented genomic DNA for 24-72 hours and the resulting 
heteroduplexes were enriched by binding to streptavidin beads. After magnetic extraction and 
several washes to remove non-targeted DNA the RNA was specifically degraded releasing 
single-stranded DNA for amplification and sequencing.  
3.2 SEQUENCE BY LIGATION 
The SOLiDTM5500xl System (AB Life Technologies, CA) is designed to enable massively 
parallel sequencing by ligation of clonally amplified DNA fragments linked to beads. Sequential 
ligation of 8 base dye-labeled oligonucleotides allowed the query of two sequential bases (di-
base encoding) with four-color competitive fluorescent detection. Following detection, 
unextended primers were capped and cleavage removed the last 3 bases and the fluorescent 
moiety. Repeated rounds of ligation and primer reset allowed each base to be read twice and 
color-space to deconcolute base-space sequences from the four possible dinucleotides coded by 
dye color. Each base was read in two independent rounds of ligation; therefore, a SNP resulted in 
two adjacent color changes. A measurement error results in a single color change, greatly 
reducing the number of false-positive SNPs and giving calling accuracies greater than 99%. 
Exact call chemistry (ECC) allowed for an additional round of primer ligation, which together 
with the two-base encoding formed an error-correction code providing highly accurate results in 
rare variant experiments such as this one. Each flowcell was divided into six lanes that could 
accommodate resequencing of two exomes.  
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3.3 INITIAL ANALYSIS 
Once raw sequencing data was returned, low quality read sequences were discarded. The rest 
were then aligned to a reference genomic sequence using either the NCBI reference sequence 
(RefSeq), or human genome reference sequence (hg19 build) using the CLC Genomics 
Workbench.  
3.3.1 Case 1 
Initial analysis was performed by You Li of Dr. Cecilia Lo’s lab. Coverage cutoff was set at 5x, 
with medium coverage of 80x. The cutoff for frequency of mutations was set at 0.25 (25%). 
Mutations with less than 25% were not recalled. Frequency designations were made as follows: 
0% for wild-type, 50% for heterozygous, and 75-100% for homozygous mutations. Data from 
HGMD, dbSNP, and 1000 genome was used to designate novel vs. reported mutations. The 
cutoff for splicing mutations was designated at 5 bases. A list was then generated of all exonic 
mutations shared by both AA and MA.  
3.3.2 Case 2 
Initial analysis of the raw sequencing data was performed by GPCL, yielding separate lists of all 
homozygous, heterozygous, insertion, and deletion mutations detected in TW’s exome. 
Frequency designations were made as follows: 0% for wild-type, 50% for heterozygous, and 75-
100% for homozygous mutations. Data from dbSNP was used to designate novel vs. reported 
mutations. 
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3.4 VARIANT ANALYSIS 
3.4.1 Case 1 
Variants were narrowed down to candidates in a step-wise manner. Given the apparent pattern of 
inheritance, the first criteria was that SNPs, insertions, and deletions be either homozygous or 
compound heterozygous and shared between AA and MM. Based on previous negative genetic 
testing and clinical suspicion that a novel mutation was responsible for the clinical phenotype, 
mutations were excluded if they were known polymorphisms or had previously been reported in 
any or all of the HGMD, dbSNP, or 1000 genome databases. Mutations were then narrowed 
based on likelihood of functional impact on the protein, beginning with mutations that were 
designated as nonsynonymous, frameshift insertion or deletion, stop-loss or stop-gain, non-
frameshift insertions or deletions, or splicing mutations. Tissue expression for the remaining 
genes was determined using the BioGPS database (http://biogps.org). Based upon the clinical 
presentation of AA and MM, genes with increased expression in brain, fetal brain, and/or 
immune system and blood cells were deemed to have “relevant” tissue expression. Genes lacking 
relevant expression, those with no information in the database, and those with even expression in 
all tissues were excluded. For compound heterozygous mutations, genes were excluded if they 
had more than 10 mutations, with the thought that these were likely to be polymorphisms and not 
relevant to the phenotype. If at any point the application of filters narrowed the list of mutations 
in a certain gene to 1, that gene was removed from further consideration. After further analysis, 
genes with more than 3 mutations were also excluded. Splicing mutations were excluded if they 
were greater than 3 bases away from an exon, with the thought that these would be less likely to 
have a functional impact on the RNA product and thus the protein. Compound heterozygous 
 22 
mutations were also examined using the SIFT and PolyPhen algorithms to predict their effect on 
the gene. After this level of analysis, the resulting candidate genes were compared to sequencing 
results from the parents and unaffected brother of AA and MM. In order to continue to be a 
candidate, the homozygous or compound heterozygous mutation could not be shared with their 
unaffected brother. Given that the clinical picture seemed to suggest autosomal recessive 
inheritance, each parent had to be a carrier of the candidate mutation if homozygous, or one of 
the compound heterozygous mutations. Though the parents are not consanguineous, their similar 
geographic origin suggests that a homozygous mutation is more likely than a compound 
heterozygous one. If particular genes were known to be associated with any disorders in the 
Online Mendelian Inheritance in Man (OMIM) database, a note was made of this as well.  
3.4.2 Case 2 
Variants were again narrowed down in a stepwise manner in two separate analysis sets. Given 
that TW was adopted and no information was available about her biological family, little 
guidance was available to hypothesize which form of inheritance most likely characterized her 
disorder. Therefore, all homozygous, compound heterozygous, insertions, and deletion mutations 
were subjected to analysis. Based on her clinical presentation, a mitochondrial disorder was 
suspected and the first round of analysis focused on mutations found in the genes contained in 
the comprehensive mitochondrial and metabolic disease panel v2.8 from Baylor Laboratories. 
The panel includes approximately 351 genes associated with approximately 180 distinct 
disorders or recognized subtypes of disorders of the mitochondria or metabolism. Candidate 
mutations matching genes in the panel were narrowed down by position in the exon, relevant 
expression, nonsynonymous mutations, and mutations unreported in dbSNP. Relevant expression 
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was designated as genes noted in the BioGPS database as having elevated expression in the brain 
or skeletal muscle, or with approximately even expression in all tissues (as this would suggest 
mitochondrial expression). If at any point the application of filters to the list of compound 
heterozygotes narrowed the list of mutations in a certain gene to 1, that gene was removed from 
further consideration. 
As analysis by the first method yielded only mildly interesting candidate mutations, a 
second round of analysis was undertaken. In this round, mutations in patient TW’s exome were 
compared to a larger database called MitoCarta, an inventory compiled by The Eli and Edythe L. 
Broad Institute of Harvard and MIT of 1013 nuclear and mtDNA genes encoding proteins with 
strong support of mitochondrial localization based on homology to mouse MitoCarta genes. 
Genes from the database not already examined in Round 1 of analysis were then subjected to the 
same analysis parameters.  
 24 
4.0 RESULTS 
4.1 CASE 1 
As shown in table 1, of the total number of mutations present in AA and MM, 20,849 were 
shared between the two siblings. 2558 were not listed in dbSNP or 1000Genome and 1647 were 
determined to be truly novel coding variants. 132 of the novel mutations were homozygous in 
both patients and 1445 were heterozygous. In the list of homozygous mutations, 86 were found 
to be the only mutation left for consideration in that gene and 43 of those were determined to 
have relevant expression patterns. After excluding splicing mutations more than 3 base pairs 
from an exon, a list of 15 candidate mutations remained. Of the 1445 heterozygous mutations, 
1088 remained after excluding genes with only a single mutation (those that were therefore not 
compound heterozygotes). Excluding genes with more than 10 mutations reduced the list to 306 
mutations, of which 124 had relevant expression. Splicing mutations more than 3 base pairs from 
an exon, genes with more than three mutations, cadherin genes, and zing finger genes narrowed 
the candidate list to 62 mutations.  
Three candidate genes were determined to be of particular interest as they show high 
expression in the brain and relate to immune system function. The variants were homozygous in 
both siblings and were confirmed by Sanger sequencing and testing of the parents and unaffected 
sibling is in progress. The DIXDC1 gene contained a c.813insC frameshift mutation in exon 10, 
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resulting in a p.S271fs mutation. The gene is expressed in the brain fetal brain, immune system, 
and blood. The ITPR2 gene contained a frameshift substitution of ACTC in exon 3 at c.1408. 
The gene is expressed in the brain, immune system, and blood. The NLRC3 gene contained a 
c.2320delC frameshift mutation in exon 10, resulting in a p.L774fs mutation. The gene is
expressed in the immune system and the blood. 
Table 1 Case 1 Homozygous Candidate Mutations 
Gene Variant Sequence 
Chance 
Amino Acid 
Change 
Expression 
ASCC3 Splicing - - 721 B lymphocytes, smooth muscle, 
bronchial epithelial 
C12orf10 Nonframeshift 
substitution 
CAA>CGC - testes, 721 B lymphocytes, even in: lung, 
liver, whole brain 
C14orf169 Frameshift insertion insC p.A87fs testis, thymus, immune/blood 
COG3 Nonframeshift 
substitution 
TTG>TCA - immune/blood, prostate, pancreas 
DDX24 Nonframeshift 
substitution 
CACGG - brain, especially pineal night/day, 
prefrontal cortex, hypothalamus 
DIXC1 Frameshift insertion insC pS271fs brain, especially retina, amygdala, 
hypothalamus, immune, fetal brain 
EI24 Frameshift insertion insC pT282fs bronchial epithelial, prostate, colon, liver, 
CD34+. CD105+ endothelial 
ITPR2 Frameshift 
substitution 
ACTC - immune/blood, brain, ganglions, blood 
coagulation, platelet activation 
KRBA1 Frameshift insertion insC p.A552 fs heart ventricle, brain, cervix, pituitary 
gland 
LEPREL2 Frameshift insertion insG p.R140fs pineal day 
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LIMD1 Splicing - - BDCA4+ dendritic cells, 721 B 
lymphoblasts 
NLRC3 Frameshift deletion delG p.L774fs immune/blood, all tissues 
PCDHB9 Frameshift insertion insA p.T381fs spinal cord, occipital lobe, hypothalamus 
SCAMP1 Frameshift insertion insA p.I244fs trigeminal ganglion, pineal night/day 
SON Frameshift insertion insA p.G2412fs immune/blood 
4.2 CASE 2 
4.2.1 Round 1 Analysis 
The results of the first round of analysis are detailed in Appendix A, tables 4, 5, and 6. TW’s 
exome was found to contain 16215 homozygous, 43999 heterozygous, 4605 insertion, and 39 
deletion mutations. In the list of homozygous mutations, 232 were located in genes on the 
reference mito chip. The list was narrowed to 76 by removing intron-located mutations, then to 
39 by removing mutations with non-relevant expression. Of that list, 22 were non-synonymous 
mutations. Removing mutations reported in dbSNP narrowed the list to 7 candidate mutations. In 
the list of heterozygous mutations, 542 were located in genes on the reference mito chip. The list 
was narrowed to only those that had two exonic mutations, for a total of 191. 64 of those had 
relevant expression patterns. Of that list, 27 were non-synonymous mutations and removing 
previously reported dbSNP mutations narrowed the candidate list to 19. Of the list of insertions, 
1505 were located in exons. 23 of those were located in genes on the mito panel and 12 had 
relevant expression. Of the deletions, 7 were located in exons. Of the candidate mutations two, a 
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Table 1 continued
compound heterozygous mutation in GFM1 and a homozygous mutation in PET112L, looked the 
most likely to be relevant but were not strikingly obvious as the causative mutations. They were 
confirmed using Sanger sequencing and were unreported in the NLHBI exome sequencing 
project database. They are also both conserved across species.  They were deemed to warrant 
further consideration if nothing more significant was found upon a second round of analysis.  
4.2.2 Round 2 Analysis 
Four lists were generated in the second round of analysis of mutations matching genes in the 
MitoCarta database that had not been investigated in the first round. This criterion generated 433 
homozygous and 1071 heterozygous mutations for further study, as detailed in table 2. In the list 
of homozygous mutations, 175 were located in exons. 102 of those 175 were non-synonymous 
mutations and 22 were also unreported in dbSNP. The list of candidate genes was then narrowed 
to 9 with relevant patterns of tissue expression. As shown in table 7 of Appendix A, 941 
mutations were found to be compound heterozygotes. Removing genes with more than 5 
mutations narrowed the list to 673 mutations. Mutations that were apparently sequencing errors, 
in which three sequential nucleotides were reported as mutation, were removed to narrow the list 
to 563. 241 of those were located in an exon. Removal of synonymous mutations narrowed the 
list to 141 mutations, of which 122 were unreported in dbSNP. Removing mutations in genes 
with non-relevant expression reduced the list of candidate compound heterozygous mutations to 
42.  
28 
Table 2 Final Candidate Gene List, all homozygous mutations 
Gene Sequence 
change 
Amino Acid 
Change 
Tissue Expression Sanger 
Sequencing 
NHLBI 
ADCK5 A>C 342K>Q even expression in all - Not found 
ABCB4 G>C 1163F>L even expression all tissues - Not found 
A>T 1163F>Y - Not found 
ATPAF2 C>G 129R>P cerebellum peduncles, 
trigeminal ganglion, even 
expression in the rest  
- Not found 
G>A 129R>W - Not found 
BCL2L2 T>G 87F>L multiple brain elevations 
(incl. prefrontal cortex, 
whole brain, hypothalamus, 
amygdala, all others) 
- Not found 
C8orf38 
(NDUFAF6) 
A>C 67K>T no data Not detected Not found 
CCDC109A G>A 238G>S even expression in all - Not found 
GFM1 A>T 609F>Y Even expression in all confirmed Not found 
GATM A>C 223Y>X kidney, fetal liver/liver, 
slight elevations in 
amygdala, prefrontal cortex, 
spinal cord) 
- Not found 
MTRR C>G 213H>Q CD4+ T cells, hypothalamus, 
pineal night/day 
- Not found 
PET112L T>A 397T>S Heart, spinal cord pending Not found 
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RAB24 A>T 32F>L no data - Not found 
SLC25A30 C>A 196M>I even expression in all - Not found 
A>G 196M>T - Not found 
SLC25A40 C>G 86G>R even expression in all - Not found 
The second round of analysis yielded one mutation of particular interest. TW was found 
to have homozygous A>C mutations at chromosome position 96044225 of the NADH 
dehydrogenase (ubiquinone) complex 1, assembly factor 6 gene (NDUFAF6, also known as 
C8orf38). This mutation resulted in a p.67K>T amino acid change and was predicted to be 
“possibly damaging” by PolyPhen-2, with a score of 0.624 (sensitivity 0.87, specificity: 0.91). 
When the variant was analyzed using SIFT it was predicted to be tolerated, with a SIFT score of 
0.17 and a median information content of 1.84. The gene is associated with mitochondrial 
complex-1 deficiency, which is the most common enzymatic defect of the oxidative 
phosphorylation disorders. It is characterized by a wide range of clinical disorders ranging from 
lethal neonatal disease to adult-onset neurodegenerative disorders.22 This is felt to be consistent 
with TW’s clinical presentation and disease course. Lysine is a positively charged polar molecule 
with a basic R group. As the side chain has three methylene groups, the side chain has significant 
hydrophobic characteristics even though the terminal amino group will be charged under 
physiological conditions. Threonine, by contrast, is a hydrophilic uncharged polar molecule with 
a non-aromatic hydroxyl as its R group and therefore the reported amino acid substitution would 
represent a change in the chemical composition and properties of the protein.  
Fibroblast samples were also still available and are in the process of being stained for 
complex-1 activity levels and super-complex assembly. Unfortunately, when Sanger sequencing 
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Table 2 continued
was undertaken it did not validate the mutation. The mutation had a coverage depth of 5x, which 
is the exact cutoff for report and therefore it represents a false positive call. Two additional genes 
in the MitoCarta gene set have been identified with variations, one involved in mitochondrial 
chromosomal maintenance (PET112L) and the other in mitochondrial protein translation 
(GFM1). Both variants are in the process of being further evaluated. 
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5.0  DISCUSSION  
5.1 CASE 1 
As has previously been discussed, the availability of family members for sequencing is an 
important factor in determining relevant candidate genes. In Case 1, analyzing the mutations 
shared between both sisters allowed for a significant reduction in the number of candidate genes 
being considered. However, due to the nature of the genes on that list and the lack of known 
associations with human disease we were unable to pinpoint a leading candidate by their 
sequencing alone. Reports in the literature have demonstrated that the more affected patients 
there are available to do sequencing on, the higher the chance of finding a causative mutation. 
However, the number of patients and/or unaffected family members necessary to discover the 
variant is going to depend on the nature of the phenotype being examined and so there is no 
recommended number. In one study of spinocerebellar ataxia in four generations of a Chinese 
family, four exome data sets were enough to determine the sole candidate gene responsible for 
the phenotype in the family.23 Other studies have needed anywhere from a single patient to ten 
family members or unrelated patients to pinpoint candidates.12 The hope is that the addition of 
three family samples will allow us to elucidate the most relevant of the candidate genes and then 
examine them further with functional studies.  
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5.2 DIFFERENTIAL DIAGNOSES FOR CASE 2 
Phenotypes of mitochondrial complex 1 deficiency include macrocephaly with progressive 
leukodystrophy, nonspecific encephalopathy, hypertrophic cardiomyopathy, liver disease, Leigh 
syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. As a 
disorder it shows significant heterogeneity and can be caused by mutations in either nuclear-
encoded genes or in mitochondrial encoded genes. The majority of cases are caused by mutations 
in nuclear encoded genes, which NDUFAF6 is. There are no obvious genotype-phenotype 
correlations and inference of the underlying basis from the clinical or biochemical presentation is 
difficult, if not impossible. Inheritance can follow either X-linked, autosomal recessive, or 
mitochondrial patterns. Mutations in the nuclear-encoded genes NDUFS1, NDUFS4, NDUFS7, 
NDUFS8, and NDUFV1 result in neurologic diseases, mostly Leigh syndrome or Leigh-like 
syndrome. 22 Before Sanger sequencing, this was felt to be the most likely of the differentials for 
patient TW. 
Given that the NDUFAF6 mutation proved to be a false positive, the GFM1 and 
PET112L mutations will be subjected to further consideration. GFM1 codes for the 
mitochondrial elongation factor G1. In order to successfully complete the elongation phase of 
protein translation, mitochondria need three functional elongation factors: Tu, Ts, and G. The 
bacterial Efg catalyzes ribosome translocation during peptide elongation and mediates ribosomal 
disassembly during ribosome recycling. In humans, the same role is divided between  EFG1 and 
EFG2, with EFG1 catalyzing the translocation component24 as well as being involved in the GTP 
catabolic process. As such, it has a number of disease associations. Defects are the cause of 
combined oxidative phosphorylation deficiency type 1 that leads to early fatal progressive 
hepatoencephalopathy. Additionally, mutations have been linked to factor 7 deficiency, 
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hemophilia B, heart aneurysms, candidiasis, and chondrosarcoma.25 The known phenotypic 
presentations of GFM1’s main associated disorder differ significantly from TW’s phenotypic 
presentation. Onset occurs at or soon after birth, with features including growth retardation, 
microcephaly, hypertonicity, axial hypotonia, encephalopathy, cardiomyopathy, and liver 
dysfunction. Death usually occurs in the first few weeks or years of life, compared to TW’s 
adult-onset presentation. 26 
PET112L is a homolog of the S. cerevisiae gene pet112. Mutations in this gene block the 
accumulation of cytochrome oxidase subunit II and disruption of the gene results in the 
destabilization of the mitochondrial genome. It is therefore suggested that the pet112 protein 
plays a major role in mitochondrial gene expression, most likely in translation. The PET112L 
protein shares 30% identity with the yeast version, contains a mitochondrial leader peptide, and 
is predominantly expressed in tissues with high rates of oxidative phosphorylation.27. Currently, 
the gene has not been associated with any genetic disorders 28, but its role in the stability of the 
mitochondrial genome suggests that dysfunction could cause mitochondrial depletion. It is 
therefore possible that such firm disease associations simply have not been made yet and the 
mutation is related to TW’s symptoms, but also that another mutation is a stronger candidate. 
Though it can be postulated, and in some cases proven, that mutations in each of these two main 
candidate genes would have widespread detrimental effects on mitochondrial function, the 
known phenotypes associated with them seem to fit less with the patient’s phenotype. However, 
recognizing that our level of genetic information about disease associations is incomplete, it is 
possible that the patient represents an atypical presentation of one of these disorders. More 
definite conclusions will have to wait for the completion of functional studies.  
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6.0  SIGNIFICANCE  
As whole-exome sequencing moves from the research setting into more widespread clinical use 
it will greatly change the landscape of what genetic testing can offer to patients. This may 
include searching for novel mutations, attempting to find a diagnosis for a patient on a diagnostic 
odyssey, or it may include diagnosing a known condition as a one-shot test in lieu of reflexing 
through genes in a panel. 
6.1 IMPACT ON GENETIC COUNSELING 
6.1.1 Ethical Issues 
The sheer quantity of information and range of possible results produced by WES raises a 
number of ethical and practical issues. Before undertaking WES with a patient the physician or 
genetic counselor needs to consider all of these aspects carefully so that they can navigate the 
process to the best advantage of the patient. In genetic counseling, the four main guiding ethical 
principles are beneficence, non-maleficence, justice, and autonomy.29 In the context of WES, 
some of these principles may come into conflict with each other in specific situations. All need 
to be weighed carefully when consenting patients and deciding what level of results to disclose 
to them.  
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6.1.1.1 Informed Consent 
Given the popularity of genomic technology in the media, it is always important to assess the 
patient’s level of knowledge, concerns, and expectations about testing. With whole-exome 
sequencing in particular, patients may have an unrealistically high expectation of a test that 
“looks at all of the genes” to deliver an answer or diagnosis. The limitations of current 
knowledge and testing should therefore be addressed in the informed consent process. The nature 
of the discussion should also be determined in part by the age of the patient and the laboratory’s 
policy regarding the return of results. It is historically not recommended for minors to undergo 
testing for conditions such as carrier status and adult onset conditions. Certain conditions may 
not be reported on at all, or reporting may be limited to adult patients only (see Appendix C for a 
comparison of clinical lab policies). Different labs might also have differing capabilities 
regarding the ability to obtain results on certain classes of mutations, such as mitochondrial 
mutations or X-linked carrier females.  
WES is a complex test for patients to understand, and even after a thorough explanation 
by a genetic counselor or researcher patients can have a difficult time explaining their 
understanding of the test or explaining the test to family members.30 Genetic counselors must 
also keep in mind the length of the discussion involved in the consent process and the amount of 
information the patient must process. Tabor et al. 2012 elicited feedback from Miller Syndrome 
patients and family members undergoing whole-genome sequencing and they reported that at 
some point the information “went in one ear and out the other”. 30 It is not practical to break the 
informed consent process into smaller pieces in a clinical setting, so genetic counselors should 
consider ways to give patients preliminary information beforehand to read, as this would give 
them an opportunity to absorb some of the information at their own pace and think of some 
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questions ahead of their session. Given the possible categories of results to choose from 
unrelated to the presenting phenotype (carrier status, adult onset conditions, pharmacogenetics, 
mitochondrial conditions, etc), extra care will be needed to ensure that the patient has a good 
understanding of the classifications and impact, and has thought about how a positive result of 
different types would affect his/her  life.  
6.1.1.2 Return of Results 
A limitation to the return of relevant results will be the level of current genetic knowledge, 
something that will be continuously changing. The WES results a patient receives today might 
have a completely different interpretation two or three years from now particularly when they 
involve variants of uncertain significance (VUS). VUS may be reclassified as pathogenic or 
benign as more data accumulates in the testing laboratories on the phenotypes of patients with 
that VUS. VUSs can also be reclassified if additional research is able to further elucidate the 
mutation’s effect on the gene and protein expression, whether through avenues such as molecular 
studies or animal models. How then should genetic counselors provide updates in VUS status to 
their patients? Is it the patient’s responsibility to contact the counselor to check for updates, as in 
the case in current BRCA1/2 testing? Or should the labs create a database of variants to allow 
them to easily contact all patients with a certain VUS if/when it gets reclassified? There are 
issues of logistics and confidentiality to consider in both cases and it is difficult to say at this 
point which would ultimately be more practical for WES. In part, it may depend on the volume 
of patients undergoing the testing and the willingness of patients to potentially have their 
information stored in such a database. As in cancer counseling, some patients may prefer to 
receive their results by phone and save themselves the trouble of having to arrange and attend a 
face-to-face appointment, but given the broad spectrum of possible results and implications in 
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WES it may not be practical to handle disclosure over the phone.  If a genetic condition is 
diagnosed by WES, it will also likely necessitate that the patient return to the clinic for a follow-
up appointment anyway to discuss the implications for their medical management.  
6.1.1.3 Pediatric versus Adult WES 
Genetic counselors and clinicians need to be aware of the varying policies that laboratories have 
regarding what classes of mutations they are willing to report on in the pediatric setting. Adult 
patients have the autonomy and authority to decide for themselves what type of results they want 
disclosed to them, whereas for pediatric patients the decision lies with their parents, and they 
may have the opportunity to receive results not generally offered to minors with other types of 
genetic tests (carrier status and adult onset conditions that will not affect their current medical 
management). Care must therefore be exercised by the pediatric genetic counselor or geneticist 
in balancing both the rights of their patient and the patient’s parents, recognizing the growing 
decision-making capabilities as adolescents mature, their right not to know certain information, 
and possibly their desire to keep certain kinds of information from their parents (specifically 
genetic information not pertinent to their current medical condition).31; 32 
6.1.2 Diagnostic odysseys and negative results 
At this point when WES is new it will likely be first used for those patients of a geneticist who 
have eluded a diagnosis through all other testing avenues. For the patient, this can mean years or 
even decades of knowing that they have a condition but not having any information on the name 
or the advantage of medical literature to guide them in anticipating what they might expect in the 
future, reproductive impact, or treatment options specifically for that condition. Unfortunately, it 
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is possible that even a powerful test such as WES may not provide an answer for them. Current 
labs are quoting diagnostic rates in the range of 34-51%33. In the research setting the rates have 
often been far lower, in the realm of 8-24%34. Regardless of which number is closer to the truth, 
it still remains a fact that they are statistically more likely not to find an answer. Families can be 
confused and frustrated by the inability of medical professionals to give them a diagnosis. The 
months, years, or decades of biochemical, genetic, and imaging tests can seem like a waste of 
time and a financial burden. Numerous feelings can be associated with such an odyssey, 
including hope, fear, depression, anger, and isolation. 35 Achieving a diagnosis for a rare disorder 
can provide many benefits for the patient and family in both the short and long term. Both 
qualitative and quantitative assessments of this impact represent an important area for future 
research as WES becomes utilized clinically, failing to receive an answer from WES may have a 
unique type or degree of impact on a patient or family’s mental well-being compared to more 
traditional tests. 
 
6.2 IMPROVED THERAPEUTIC OPTIONS 
Gene discovery is an essential first step in the process of understanding the genetic and 
biochemical mechanisms of inherited diseases, and for providing clues to direct research into 
therapies. Gene-specific treatments are currently being undertaken worldwide and there have 
been a number of successful gene-therapy trials aimed at correcting the inborn errors causing 
immune deficiencies, metabolic disorders, and more recently thalassemia.1 Local deliver of 
replacement genes is also being tested in human clinical trials for several forms of hereditary 
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blindness such as Leber congenital amaurosis and retinitis pigmentosa. The elucidation of a 
wider range of causative genes can only lead to a further broadening of the conditions eligible for 
this kind of research.  Beyond gene therapy, understanding of the genetic and biological 
mechanisms of the conditions can lead to knowledge of what currently-existing treatments and 
therapies could be applied, or how current treatment techniques such as enzyme replacement 
therapy might be altered for the specific needs of affected individuals.  
Worthey et al (2011) reported a case in which WES was successfully used to diagnose an 
infant with a severe gastro-intestinal presentation of inflammatory bowel disease requiring a 
cholectomy and ileostomy that, despite a thorough clinical evaluation and extensive genetic 
testing, was unable to be definitively given a diagnosis. WES detected a novel hemizygous 
mutation in the X-linked inhibitor of apoptosis gene, leading to a diagnosis of X-linked inhibitor 
of apoptosis deficiency and the identification of a novel cause of IBD. This diagnosis allowed the 
child to receive an allogenic hematopoietic progenitor cell transplant, which is the recommended 
treatment for the condition, to prevent the development of life-threatening hemophagocytic 
lymphohistiocytosis. The gastrointestinal disease also resolved post-transplant, suggesting that 
the mutation underlay those symptoms as well. 36 
WES can also be used to drive clinical care in instances of a known diagnosis of 
unknown genetic etiology. In the case of a set of male and female twins diagnosed clinically with 
Dopa (3,4-dihydroxyphenylalanine)-responsive dystonia (DRD), mutation analysis of the two 
primary genes (TH and GRP) yielded no results. Sequencing of a third gene, SRP, was not 
available clinically, so WES was performed, detecting compound heterozygous mutations in 
SRP. The clinical diagnosis of DRD was sufficient to start the twins on L-dopa treatment, but 
patients display a range of responses to such therapy and L-dopa alone may not completely 
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alleviate symptoms, such as in this case. As SRP encodes sepiapterin reductase, which 
synthesizes a cofactor needed for the action of enzymes that make both dopamine and serotonin, 
identification of the SRP mutation suggested that supplementing L-dopa with the serotonin 
precursor 5-hydroxytryptophan might further improve symptoms. This proved to be the case. 
Interestingly, the mutations also co-segregated in the family with a fibromyalgia phenotype. 
Fibromyalgia can respond to serotonin reuptake inhibitor drugs (SSRIs), suggesting that the 
disease is related to reduced serotonin, and the authors hypothesized that loss-of-function SRP 
mutations might therefore contribute to fibromyalgia susceptibility. 37 
Sometimes, WES can be used to rule-out treatments that would not ultimately improve 
the individual’s state of health. An infant with acute liver failure was found to have a recessive 
disorder due to mutations in C10orf2 (TWINKLE) that resulted in mitochondrial DNA depletion. 
In this case, the diagnosis allowed the parents to be counseled that the infant would not be an 
appropriate candidate for a liver transplant. Though liver transplantation is the treatment of 
choice for liver failure, it has been shown to be futile in one form of mtDNA depletion and to 
have similar poor long-term outcomes in others. Though this sadly was not an answer that led to 
a treatment, it allowed the parents to have knowledge of the progression and outcome that they 
could expect for their child, and to spare themselves and their child a major, invasive operation 
that would have been extremely expensive and ultimately not beneficial. 38  
6.3 LIMITATIONS 
As with any type of research there exist opportunities for error in the analysis of these two case 
examples. As the analysis process is not an automated one, naturally there is the chance for 
 41 
human error in the input, examination, and interpretation of the data and its relevance to the 
research question. The variant filtering strategy used follows closely with the pipeline suggested 
in the literature, but with some deviations in the order of the application of certain filters.  This 
influenced the type of variants filtered out at each stage and lead to some variants making it to 
higher or lower levels of consideration that perhaps is warranted. The interpretation of data is 
also limited by the current level of knowledge about the genes studied and the information 
available in databases such as dbSNP, BioGPS, OMIM, and others. As previously discussed, 
there is a certain level of misclassification of variants in some databases and other databases 
reflect our incomplete knowledge about the function and disease associations of certain genes 
that may also lead to candidate variants being erroneously discarded. This project also utilized 
different labs for the sequencing and initial analysis of each case. Ideally, the same lab and 
analysis process should be used with each new patient to maintain the greatest concordance 
between the resulting data sets. Sequencing of the exome also achieved lower coverage of target 
regions than is possible and ideal by clinical standards, in the range of 4-136x for Case 2 with an 
average read depth of 14.12x and only 21% of calls at a read depth of 20x or greater. The lower 
the coverage level is, the higher the chances for both false positives and false negatives, as 
demonstrated by the red herring mutation in NDUFAF6. This is not always necessarily the case, 
as Dr. Vockley’s lab has confirmed mutations by Sanger sequencing read at a coverage of 4x, but 
the general trend should be noted. A 30x median coverage of the target may be sufficient, but 
100x coverage is better to ensure that variants can confidently be determined for a higher 
proportion of the exome.1 Approximately 3.5-8% of variant calls in WES will be false positives 
with current technology5, and the total percentage of false calls may be higher, in the range of 
15-20%. False positive calls are most often due to incorrect mapping and systematic sequencing 
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errors such as certain combination of nucleotides being routinely misread by the sequencer. False 
negatives are typically the result of low overall coverage, poor capture efficiency of certain 
regions, and difficulty in unambiguously aligning repetitive regions. One strategy to reduce these 
errors is to compare each test sample against previously sequenced exomes, and missing regions 
are relatively easy to flag and report, to be followed up with more targeted sequencing if the 
researcher chooses.1  
The cases studied here also demonstrate the challenges of sequencing single patients and 
the need to include other family members for comparison whenever possible. Not only is it 
useful for elucidating risks to other family members based on carrier status or possession of the 
same deleterious mutation, but it also provides a way to better classify certain variants as more 
likely to be benign based on the presence in unaffected family members. If a family member 
shares the same phenotype, such in Case 1, comparison to the affected individuals provides a 
good candidate list from which to then weed out variants based on the genetic status of 
unaffected family members. However, a researcher should use caution when ruling out variants 
by this method in the case of a suspected autosomal dominant condition, recognizing the 
limitations imposed by variable expressivity and incomplete penetrance that may lead to the 
premature discarding of the pathogenic mutation. Classification is easier when autosomal 
recessive inheritance is more likely, given the more penetrant and phenotypically noticeable 
effects of such conditions.  
In this study, closer examination of the shared candidate mutations in the patients needed 
to wait until sequencing data was available from their parents, as samples had been collected at a 
later time from them. Potentially the siblings could have had a shorter list of candidate genes or 
more striking candidates, in which case delaying the collection and sequencing of parental 
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samples would have proven a cost-saving measure. As in this case, it instead resulted in a delay 
of results by several months, drawing out the family’s search for answers to a traumatic situation 
and leaving then unsure whether to plan future pregnancies. It is therefore my opinion that in 
such a case, samples from the affected individuals and their parents should all be collected and 
analyzed together. Then if necessary, samples from other pertinent individuals in the pedigree 
can be collected.  
As Case 2 demonstrated, using existing databases runs the risk of also discarding 
plausible candidate mutations when filters are too stringently applied. Some genes have no data 
on tissue expression available in BioGPS, a situation likely common to all such databases, and 
simply discarding such genes would have resulted in the candidate NDUFAF6 mutation being 
overlooked. However, as Sanger sequencing ultimately discredited the finding of the mutation, it 
also highlights the need in both the research and clinical settings to confirm the effects of 
suspicious mutations by other means whenever possible. Particularly when computer algorithms 
of the pathogenicity of the mutation are not in concordance, functional studies of enzyme activity 
or other biomarkers can disprove or lend credence to the finding. Given that this would incur 
additional time and expense, such methods should only be used to examine the most likely 
relevant findings. In the clinical setting, laboratories may have more resources with which to 
examine candidate variations and draw firmer conclusions about their significance on the first 
round of analysis. In contrast, in the research setting there exists a greater freedom to run 
samples through alternate analysis filters, such as re-examining Case 2 using MitoCarta, and 
spend more time closely examining a single data set.  
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6.4 FUTURE DIRECTIONS 
Whole exome sequencing is just now entering the phase of broader utilization of its capabilities 
and as such there exist many opportunities for further research and expansion of knowledge. 
Researchers need to continue to study individual genes and conditions to elucidate the genotype-
phenotype correlations so essential to the accurate interpretation of WES data. WES results will 
themselves play a part, in determining the genetic bases of certain disorders. Further research is 
also needed into the clinical impact of WES, on the patients, genetic counselors, and physicians 
who are the beneficiaries and utilizers of the technology. We need to understand the perceptions, 
psychosocial impact, biases, and logistical impact that the test has in the clinical setting to a 
better degree than we do now as its use is increasing in clinical practice. Such research will allow 
us to apply this type of testing with the fullest degree of awareness, sensitivity, and efficacy, as 
possible.  
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7.0  CONCLUSION 
In summary, recent advances in exome sequencing are accelerating the pace of gene discovery 
for Mendelian disorders. Studies such as this one demonstrate the degree of complexity that 
researchers encounter as they analyze such sequencing data on gene-discovery studies and the 
need for continued research to expand our knowledge of genes and their physiological impact so 
that new associations with human disease can be made. Even though WES represents a powerful 
new diagnostic tool for patients, there are still limitations to its capabilities, as demonstrated by 
the results of this study and the difficulty in finding causative mutations for these three patients.   
As WES is enters the clinical practice, genetic counselors will play an important role in 
helping patients navigate the process and understand the impact of the results on their lives. It 
will take time to fully appreciate the logistical impact that such a test will have on the clinic, but 
clinicians will have to be aware of the financial, ethical, and psychosocial issues that arise in the 
context of such testing. As WES becomes a standard component of genetic diagnosis, it will also 
be extremely important to educate the public about how this technology can be used.  
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APPENDIX A 
SUPPLEMENTARY TABLES 
Table 3 Case 1 Compound Heterozygous Candidate Mutations 
Gene Mutation Type Sequence change Amino Acid 
Change 
Tissue Expression 
ANKRD36 nonframeshift 
substitution 
c.11883_1185TGT - CD8+ T cells, pineal day 
nonsynonymous c.G1186T p.V396F
nonsynonymous c.T1697C p.I566T
ANKRD38B nonframeshift 
substitution 
c.2731_2733ACG pineal night/day, CD8+ and 
CD4+ T cells  
nonframeshift 
substitution 
c.3124_3126TGT
nonsynonymous c.C3127G p.R1043G
C8orf59 nonframeshift 
substitution 
c.259_264AATGTT immune/blood 
nonsynonymous c.G265A p.D89N
CNN2 nonsynonymous c.G630A p.M210I immune/blood 
nonsynonymous c.G747A p.M249I
nonsynonymous c.T629C p.M210T
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DCD5 nonsynonymous c.C2041A p.L681I  fetal brain, brain, spinal cord, 
ovary, hippocampus, 
bronchus, atrioventricular 
node, liver, lung  
nonsynonymous c.T821G p.F274C
EXOG stop loss c.A956G p.X319W All tissues, 721 B 
lymphoblasts, multiple brain 
elevations (cerebellum, 
hypothalamus, whole brain, 
cerebellum peduncles)  
nonsynonymous c.C953T p.S318F
FAM38A nonframeshift 
substitution 
c.5632_5634--- immune/blood, pineal 
night/day  
nonsynonymous c.G6411C p.M2137I
FAM8A1 nonsynonymous c.A395G p.H132R whole blood, CD56+ NK 
cells,  many brain elevations 
(prefrontal cortex, amygdala, 
pineal night/day, fetal brain, 
hypothalamus, spinal cord)  
nonsynonymous c.G401T p.G134V
nonsynonymous c.G418A p.A140T
HSPA9 nonsynonymous c.A1900G p.R634G 721 B lymphoblasts 
nonsynonymous c.G1906A p.A636T
IBTK nonframeshift 
substitution 
c.4057_4059TAT 721 B lymphoblasts, CD33+ 
myeloid, pineal night/day  
nonsynonymous c.C4013T p.T1338I
nonsynonymous c.G3970C p.E1324Q
LARP7 nonsynonymous c.C1508T p.A503V immune/blood, pineal 
night/day, thyroid  nonsynonymous c.G1504A p.D502N
MEX3D frameshift insertion c.525_526insG p.K175fs relatively even in all, some 
elevations in brain  nonframeshift c.535_537ACC
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Table 3 continued
substitution 
MLL3 nonsynonymous c.C2578T p.P860S placenta, thyroid gland, 
blood, bone marrow  nonsynonymous c.G2573T p.W858L
MRPS17 nonsynonymous c.G247A p.E83K CD105+ endothelial, 721 B 
lymphoblasts, bronchial 
epithelial  
nonsynonymous c.T242A p.L81Q
nonsynonymous c.T298C p.C100R
MTCH2 nonframeshift 
substitution 
c.235_237CAT testes, 721 B lymphoblasts, 
CD105+ endothelial, CD34+ 
stop gain c.A229T p.R77X
NRBF2 nonsynonymous c.A517T p.T173S whole blood 
nonsynonymous c.T524C p.I175T
ONECUT3 nonframeshift 
substitution 
c.564_566--- adrenal gland cortex, 
pancreas, accumbens, 
putamen  nonsynonymous c.C581G p.A194G
nonsynonymous c.G1333A p.V445I
PARG nonsynonymous c.C77T p.S26L superior cervical ganglion, 
testes, skeletal muscle, 
immune/blood  
nonsynonymous c.A1720G p.I574V
PCSK6 nonsynonymous c.C1454T p.S485F liver, spinal cord, other 
smaller brain elevations nonsynonymous c.T1490C p.I497T
PDCD7 frameshift deletion c.329delC p.P110fs pineal night/day 
stop gain c.C193T p.R65X
nonsynonymous c.C197T p.A66V
ROCK2 nonframeshift 
substitution 
c.487_489CGT multiple brain areas, esp. 
prefrontal cortex, cingulate 
cortex, caudate nucleus  nonframeshift 
substitution 
c.538_540TTA
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Table 3 continued
RSL24D1 nonsynonymous c.C430G p.Q144E immune/blood, bronchial 
epithelial, pineal night/day nonsynonymous c.C487T p.P163S
nonsynonymous c.G463C p.E155Q
SALL2 nonsynonymous c.C2140A p.L714M brain, esp. pineal night/day, 
cerebellum, cerebellum 
peduncles  
nonsynonymous c.G2128A p.V710I
SRP19 stop gain c.A124T p.K42X immune/blood 
nonframeshift 
substitution 
c.277_279CGA
nonsynonymous c.G261A p.M87I
TERF1 nonsynonymous c.C250T p.L84F prefrontal cortex, pineal 
night/day, amygdala  nonsynonymous c.T240G p.D80E
USP6 nonsynonymous c.C202T p.R68W testes, prefrontal cortex, fetal 
brain, appendix  nonsynonymous c.T362C p.L121S
Table 4 Case 2 Round 1 Compound Heterozygous Candidate Mutations 
Gene Mutation type Sequence 
change 
Amino Acid 
Change 
Tissue Expression 
ATPAF2  - G>CG 161I>MI cerebellum peduncles, trigeminal ganglion, 
even among rest - A>AT 161I>IN 
- G>CG 128I>MI 
 - A>AG 128I>IT 
GFM1 Non Synonymous T>AT 512Y>NY even expression in all tissues 
Non Synonymous G>CG 513G>RG 
HLCS  - T>CT  - even expression in all tissues 
Non Synonymous T>AT  - 
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Table 3 continued
MUT  - A>AT  - pineal night/day, prefrontal cortex, CD34+ 
Non Synonymous T>CT 621K>RK 
PYGM Non Synonymous C>AC 790A>A skeletal muscle, thyroid 
Non Synonymous T>CT 236N>SN 
Non Synonymous G>AG 71T>MT 
RET Non Synonymous G>CG 106W>SW skeletal muscle, uterus corpus, even 
expression in rest Non Synonymous G>CG 106W>CW 
Non Synonymous G>CG 584D>D 
UBE3A  - A>AC  - brain, thyroid 
- A>AT - 
 - T>AT  - 
Table 5 Case 2 Round 1 Insertion Candidates 
Gene Sequence Change Amino Acid Change Tissue Expression 
COX4I1 insA - heart, multiple minor brain and immune/blood 
elevations 
COX7A2L insC FS pineal night/day, retina, immune/blood 
FASTKD2 insA FS relatively even in all 
GFM2 insT FS even in all, elevation in 721 B lymphoblasts 
HADHB insT FS immune/blood, spinal cord, hypothalamus, skeletal 
muscle, small intestine 
LARS2 insA;AT FS relatively even in all 
insG;CT FS 
MARS2 insG FS relatively even in all 
NDUFB9 insG - heart, immune/blood, small brain elevations 
PDHA1 insA FS pineal night/day, amygdala, spinal cord, lymphoma 
SLC25A19 insG FS no data 
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Table 4 continued
VARS2 insT;CT FS relatively even in all 
Table 6 Case 2 Round 1 Exonic Deletions 
Gene Sequence Change Amino Acid Change 
CCDC80 delT FS 
PIK3R1 delT - 
PCDHB9 delG FS 
BRPF3 delG - 
ABCC8 delG FS 
DDHD1 delAG - 
NLRP7 delG FS 
CCDC80 delT FS 
PIK3R1 delT - 
PCDHB9 delG FS 
Table 7 Case 2 Round 2 Compound Heterozygous Candidates 
Gene Sequence change Amino Acid Change Tissue Expression 
ADCK4 T>AT 299Q>LQ even expression in all 
G>GT 299Q>KQ 
ADHFE1 T>AT 309H>QH no data 
A>AG 310M>MV 
AMACR T>GT 310K>KQ even expression in all 
C>AC 242E>XE 
G>GT 241Y>XY 
ARMC4 G>CG 276T>RT even expression in all 
T>AT 276T>ST 
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Table 5 continued
DDX28 A>AT - even expression in all 
T>AT  - 
FOXRED1 A>AG 33K>KE no data 
T>CT 130F>F 
GHITM T>AT 327L>XL multiple brain elevations (prefrontal cortex, pineal 
night/day, amygdala, hypothalamus, etc.) A>AT 327L>LF 
A>AG 328N>NS 
GLS T>GT 231I>IM multiple brain elevations (occipital lobe, parietal lobe, 
prefrontal cortex, globus pallidus, etc.)  G>GT 232D>YD 
GOT2 C>CG 721 B lymphoblasts, liver, whole brain, pineal 
night/day, retina  G>CG 78P>AP 
HSPA9P A>AC - no data 
A>AG - 
A>AC  - 
IDH3G G>AG 354A>VA heart, immune/blood, minor brain elevations (whole 
brain, amygdala, pineal night/day)  C>CT 354A>AT 
IREB2 C>AC - superior cervical ganglion, trigeminal ganglion, 
skeletal muscle T>GT  - 
LDHD A>AG - liver, even expression in rest 
A>AG - 
G>AG 218P>SP 
NFXL1 G>GT 248L>IL no data 
C>AC 247W>CW 
PHYHIPL A>AG 85I>IV multiple brain elevations, including prefrontal cortex, 
amygdala, whole brain, occipital lobe  T>CT 85I>TI 
PPTC7 G>CG - even expression in all 
A>AT  - 
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Table 7 continued
SLC25A33 C>CG 87P>PA no data 
A>AG 160Q>QR 
TIMM50 A>AC - even expression in all 
T>CT - 
VAMP1 T>CT - multiple brain elevations, including prefrontal cortex, 
thalamus, spinal cord, parietal lobe, etc.   T>CT  - 
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Table 7 continued
APPENDIX B 
CONSENT FORMS 
Adult Consent Form 
Division of Medical Genetics 
Gerard Vockley, M.D., Ph.D. 
Chief 
One Children’s Place 
4401 Penn Avenue 
Pittsburgh, PA 15224 
Ph: (412) 692-5070 
Fx: (412) 692-6472 
CONSENT FOR AN ADULT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
TITLE: Use of whole exome and genome sequencing to identify new genetic disorders 
Research Project 
Director: 
Gerard Vockley, M.D., Ph.D., Chief of Medical Genetics 
University of Pittsburgh School of Medicine;  
Telephone: 412.692.7746 
Other Key Research Team Members 
Lina Ghaloul Gonzalez, 412.692.5070 Stephanie DeWard 412-692-5232 
M. Michael Barmada, 412.383.7959 
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David Peters 412.624.5392  
Nancy Perrott, 412.692.3150  
  
SOURCE OF SUPPORT: Division discretionary funds 
 
We are conducting research to understand the genetic basis for unknown genetic conditions. 
There are many genetic disorders which have already been identified.  However, in some individuals, we 
may still suspect a genetic disorder even though a precise diagnosis is unknown. As a result of your/your 
family member’s medical history and clinical testing, the genetic doctor thinks you/your family member 
(s) may have an unknown genetic disorder.  
  
Your genetic material is a substance within the body, such as DNA and RNA, which is passed 
down from parents to children and can affect what types of diseases people have.  DNA or 
deoxyribonucleic acid is the chemical inside the central part of a cell that carries the genetic instructions 
in humans and almost all organisms and makes the individual hereditary characteristics; RNA or 
ribonucleic acid is a chemical similar to single strand of DNA and determines the protein synthesis and 
the transmission of genetic information.  In this study we will be studying genetic material from your 
blood.  This research study will use new techniques to read all of the genetic information in your cells 
that might cause a health problem if it contained a mistake. These techniques are called whole exome 
and genome sequencing.   
We are inviting you to participate in this study because the genetic doctor thinks you/your 
family member (s) may have a genetic disease. This study will allow us to test conditions to best 
sequence all the important DNA from individuals in your situation. We may also be able to identify the 
genetic cause of your/ your family’s medical condition. 
 56 
As part of this study, you will complete the following procedures in addition to tests ordered 
by your physician for routine care.  Two tubes of blood will be drawn from you in the in the phlebotomy 
lab at Children's Hospital of UPMC by the lab personnel after the clinic visit and being seen by your 
medical genetics doctor The amount of blood in each tube will not exceed 10 ml total volume (about 2 
teaspoons). The blood will then be frozen immediately and sent to the lab performing the DNA 
sequencing. No other procedures will be necessary for you to participate in this study.  
There will be no need for specific follow-up appointments or outpatient visits related to this 
research study until we have the result of the research study which will be disclosed to you during a 
clinic visit regardless of being positive or negative. Positive results will be confirmed in a CLIA lab before 
being disclosed. Each subject will get his/her own result and not of the whole family. 
We are also requesting your authorization or permission to review your medical records to 
record past, current, and future medical information from hospital and other medical facilities. We will 
obtain information concerning your diagnosis, health and family history, and results of any physical 
exams, tests of urine, blood, tissues, and any other tests, including results of genetic tests.  We will use 
this information to determine whether you meet the conditions for participation in this study, and to 
help us understand the results of the genetic tests performed as part of this study.  This identifiable 
information will be made available to members of the research team, for an indefinite period of time. 
The University of Pittsburgh Research Conduct may monitor this study and as the result of this 
monitoring may have access to your identifiable information.   
We are also requesting your permission to re-contact you in the future regarding participation 
of your family/relatives in this study.  You may refuse to be re-contacted in the future. Your decision will 
not affect your relationship with the University of Pittsburgh or the UPMC, nor will you lose any benefits 
that you might be eligible for because of this decision  
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Results of the research study will be disclosed to the subjects during a medical genetic clinic 
appointment with appropriate genetic counseling and plans for clinical follow up and testing. After the 
research study and verification studies are completed, your DNA sample will be stored indefinitely for 
future molecular studies related to the subject’s condition and to compare to future planned whole 
exome/whole genome sequencing studies. This will be done by same researchers of this study. Upon 
participation in the research study and when stored, these samples will be given a case number and the 
code linking the name to this number will be maintained separately with very limited access to research 
team. 
There are a number of possible risks, side effects, and discomforts associated with 
participation in this research study.  The risks of each procedure are minimal and rare. 
• Blood draws: Brief discomfort, bruising, slightly prolonged bleeding, infection at the site, scar 
noted at the site, the clotting of blood around the site, or fainting.  Care will be taken to avoid 
these potential risks and discomforts. The blood draw will be obtained at the same time as other 
blood tests that your doctor will order for your routine care.  If you are not having blood drawn 
for routine care, we will draw the blood during your study visit. 
• Because your genetic information is being used in this research study, there is a rare risk that 
information could become accessible to people other than members of this research team.  
Breaches in confidentiality involving genetic information could impact future insurability, 
employability, or reproduction plans, or have a negative impact on family relationships, and/or 
result in paternity suits or stigmatization.  To minimize these risks, genetic information (as well 
as your medical information) will only be recorded in files marked with case numbers, not your 
name. 
• There is also a possibility of learning life-altering results. This will be managed by the 
appropriate counseling, support and provide the patient with the available treatment.  
A new Federal law, called the Genetic Information Nondiscrimination Act (GINA), generally 
makes it illegal for health insurance companies and group health plans to use genetic information in 
making decisions regarding your eligibility or premiums. GINA also makes it illegal for employers with 15 
or more employees to use your genetic information when making decisions regarding hiring, promoting, 
firing, or setting the terms of employment. This new Federal law does not protect you against genetic 
discrimination by companies that sell life, disability, or long-term care insurance. 
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If we learn of any new information about study risks that could cause you to change your mind 
about continuing to participate, we will notify you promptly. 
Benefits of participation in this research study: There is no benefit to participation in this 
research study other than possibly increased knowledge about your/your family’s disease. If a specific 
genetic disorder is identified, specific treatment may be available based on the information. 
None of the procedures you receive during this research study (research blood draws or 
genetic analysis) will be billed to you or your health insurance.  If you get a bill or believe your health 
insurance has been billed for something that is part of the study, notify a member of the research team.  
However, you or your insurer will be billed for all other usual care services, including routine surgery, 
blood draws for clinical/routine care, follow-up care, or testing done for clinical/routine purposes.  
You will not be paid for your participation.  Although it is possible that your biological samples 
may lead, in the future, to new inventions, discoveries or products that may be sold, licensed, or 
patented, there are currently no plans to share with you any money or other rewards that may result 
from the development of those new products.  
If you believe that the research procedures have resulted in an injury to you, immediately 
contact Dr. Vockley or a member of the Research Team (see first page). Emergency medical treatment 
for injuries solely and directly related to your participation in this research study will be provided to you 
by the hospitals of UPMC. Your insurance provider may be billed for the costs of this emergency 
treatment, but none of those costs will be charged directly to you. If your research-related injury 
requires medical care beyond this emergency treatment, you will be responsible for the costs of this 
follow-up care. At this time, there is no plan for any additional financial compensation.  
To protect your privacy and maintain the confidentiality of information we obtain from you 
and from your medical records, we will maintain all information about you in a secure location. This 
research study will involve the recording of current and/or future identifiable medical information from 
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your child’s hospital and/or other (e.g., physician office) records.  The information that will be recorded 
will be limited to information concerning your child’s genetic disorder.  All paper records that could 
identify you will be stored in locked file cabinets, and all electronic records will be stored in password-
protected files. Your identity on these records will be indicated by a case number rather than by your 
name, and the code linking your name to this number will be maintained separately with very limited 
access to research team members.  Although we will do everything in our power to protect your privacy 
and the confidentiality of your records, just as with the use of your medical information for health care 
purposes, we cannot guarantee the confidentiality of your research records, including information that 
we obtained from your medical records. However, no third party, including relatives, personal 
physicians or insurance companies, or other researchers will have access to your identifiable 
information, with one exception. Authorized representatives of the UPMC hospitals may have access to 
identifiable information only for the purpose of (1) filling orders made by the researchers for hospital 
and health care services (e.g., laboratory tests) associated with the research study, (2) addressing 
correct payment for tests and procedures ordered by the researchers, and/or (3) for internal hospital 
operations (e.g., quality assurance).  Also, authorized representatives from the University of Pittsburgh 
Research Conduct and Compliance Office will have access to these files but only for the purpose of 
monitoring the conduct of the study.  
Your doctor may also be involved as an investigator in this research study, but you are not 
under any obligation to participate in any research study offered by your doctor. Before agreeing to 
participate in this research study, or at any time thereafter, you may wish to discuss participation in this 
study with another health professional, to obtain a ‘second opinion’ about study participation.  You may 
also contact the University ‘Research Participant Advocate’ 1-866-212-2668 for additional information.   
Your participation in this research study is completely voluntary. Whether you participate/not 
participate in this research study will have no effect on your current or future relationship with the 
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University of Pittsburgh, UPMC or its affiliated health care providers or health care insurance providers.  
If you decide you no longer wish to continue to participate after you have signed the consent form, you 
should contact Dr. Vockley or his colleagues. Your blood samples and DNA will then be destroyed if they 
are not in the midst of being analyzed. You may also withdraw, at any time, your authorization to allow 
the research team to review your medical records, but if you do so, you will no longer be permitted to 
participate in this study.  Any information obtained from you up to that point will, however, continue to 
be used by the research team.  Your decision to withdraw from this study will have no effect on your 
current or future relationship with the University of Pittsburgh or with UPMC or its affiliated health care 
providers or health care insurance providers. However if withdrawal takes place, no information 
regarding results will be returned to you and your DNA sample will be destroyed so that no additional 
future testing can be performed. Results from the sequencing study obtained prior to withdrawal will 
still be analyzed to the extent possible. 
VOLUNTARY CONSENT:  
All of the above has been explained to me and all my current questions are answered. I 
understand I am encouraged to ask questions and voice concerns or complaints about any aspect of this 
research during the course of it, and that those questions, concerns, or complaints will be answered by 
the researchers listed on the first page of the form. I understand that I may always request that my 
concerns be addressed by a listed investigator. I understand that I may contact the Human Subjects 
Protection Advocate of the IRB Office, University of Pittsburgh (1-866-212-2668) to discuss any issues; 
obtain information; offer input; or discuss situations in the event that the research team is not available. 
By signing this form, I agree to participate in this research study. A copy of this consent form will be 
given to me.  
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____________________________________                                    
Participant’s Name (Print)                         
 
 
____________________________________                     ---------------------------------------
Participant’s Signature            Date 
 
CERTIFICATION of INFORMED CONSENT:  
 
I certify that I explained the nature and purpose of this research study to the above-named 
individual(s). I discussed the potential benefits and possible risks of study participation. Any questions 
the individual(s) have about this study have been answered, and we will always be available to address 
future issues that arise. I certify that no research component of this protocol was begun until after this 
consent form was signed. 
 
____________________________________ ______________________  
Printed Name of Person Obtaining Consent                                              Role in Research Study  
 
_____________________________________ ______________________  
Signature of Person Obtaining Consent                   Date 
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Pediatric Consent Form 
 
Division of Medical Genetics 
Gerard Vockley, M.D., Ph.D. 
Chief 
One Children’s Place 
4401 Penn Avenue 
Pittsburgh, PA 15224 
Ph: (412) 692-5070 
Fx: (412) 692-6472 
CONSENT FOR A CHILD TO ACT AS A PARTICIPANT IN A RESEARCH STUDY  
TITLE: Use of whole exome and genome sequencing to identify new genetic disorders 
Research Project  
Director: 
Gerard Vockley, M.D., Ph.D., Chief of Medical Genetics 
University of Pittsburgh School of Medicine;  
Telephone: 412.692.7746 
 
Other Key Research Team Members 
Lina Ghaloul Gonzalez, 412.692.5070 Stephanie DeWard 412-692-5232 
M. Michael Barmada, 412.383.7959 Nancy Perrott, 412.692.3150 
David Peters 412.624.5392  
   
SOURCE OF SUPPORT: Division discretionary funds 
We are conducting research to understand the genetic basis for unknown genetic conditions. 
There are many genetic disorders which have already been identified.  However, in some individuals, we 
may still suspect a genetic disorder even though a precise diagnosis is unknown. As a result of your 
medical history and clinical testing, your genetic doctor thinks your child/ your family member(s) may 
have an unknown genetic disorder.  
Your genetic material is a substance within the body, such as DNA and RNA, which is passed 
down from parents to children and can affect what types of diseases people have.  DNA or 
deoxyribonucleic acid is the chemical inside the central part of a cell that carries the genetic instructions 
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in humans and almost all organisms and makes the individual hereditary characteristics; RNA or 
ribonucleic acid is a chemical similar to single strand of DNA and determines the protein synthesis and 
the transmission of genetic information.  In this study we will be studying genetic material from your 
child’s blood.  This research study will use new techniques to read all of the genetic information in 
his/her cells that might cause a health problem if it contained a mistake.  These techniques are called 
whole exome and genome sequencing.   
We are inviting your child to participate in this study because the genetic doctor thinks your 
child /your family member (s) may have a genetic disease. This study will allow us to test conditions to 
best sequence all the important DNA from individuals in your situation. We may also be able to identify 
the genetic cause of your/ your family’s medical condition. 
As part of this study, your child will complete the following procedure.  Two tubes of blood will 
be drawn from your child in the in the phlebotomy lab at Children's Hospital of UPMC by the lab 
personnel after the clinic visit and being seen by your medical genetics doctor The amount of blood in 
each tube will not exceed 10 ml total volume (about 2 teaspoons). The blood will then be frozen 
immediately and sent to the lab performing the DNA sequencing. No other procedures will be necessary 
for you to participate in this study.   
There will be no need for specific follow-up appointments or outpatient visits related to this 
research study until we have the result of the research study which will be disclosed to the 
parents/guardians during a clinic visit regardless of being positive or negative. Positive results will be 
confirmed in a CLIA lab before being disclosed. 
We are also requesting your authorization or permission to review your child’s medical 
records to record past, current, and future medical information from hospital and other medical 
facilities. We will obtain information concerning your child’s diagnosis, health and family history, and 
results of any physical exams, tests of urine, blood, tissues, and any other tests, including results of 
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genetic tests.  We will use this information to determine whether your child meets the conditions for 
participation in this study, and to help us understand the results of the genetic tests performed as part 
of this study.  This identifiable information will be made available to members of the research team, for 
an indefinite period of time. The University of Pittsburgh Research Conduct may monitor this study and 
as the result of this monitoring may have access to your child’s identifiable information.   
We are also requesting your permission to re-contact you in the future regarding participation 
of your family/relatives in this study.  You may refuse to be re-contacted in the future. Your decision will 
not affect your relationship with the University of Pittsburgh or the UPMC, nor will you lose any benefits 
that you might be eligible for because of this decision  
Results of the research study will be disclosed to you during a medical genetic clinic 
appointment with appropriate genetic counseling and plans for clinical follow up and testing. After the 
research study and verification studies are completed, your child’s DNA sample will be stored 
indefinitely for future molecular studies related to the subject’s condition and to compare to future 
planned whole exome/whole genome sequencing studies. This will be done by same researchers of this 
study. Upon participation in the research study and when stored, these samples will be given a case 
number and the code linking the name to this number will be maintained separately with very limited 
access to research team.   
There are a number of possible risks, side effects, and discomforts associated with 
participation in this research study.  The risks of each procedure are minimal and rare, and occur in less 
than 1 time out of 100. 
• Blood draws: Brief discomfort, bruising, slightly prolonged bleeding, infection at the site, scar 
noted at the site, the clotting of blood around the site, or fainting.  Care will be taken to avoid 
these potential risks and discomforts. The blood draw will be obtained at the same time as other 
blood tests that your doctor will order for your child’s routine care.  If your child is not having 
blood drawn for routine care, we will draw the blood during their study visit. 
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• Because your child’s genetic information is being used in this research study, there is a rare 
risk that that information could become accessible to people other than members of this 
research team.  Breaches in confidentiality involving genetic information could impact future 
insurability, employability, or reproduction plans, or have a negative impact on family 
relationships, and/or result in paternity suits or stigmatization.  To minimize these risks, genetic 
information (as well as medical information) will only be recorded in files marked with case 
numbers, not your child’s name.    
• There is also a possibility of learning life-altering results. This will be managed by the 
appropriate counseling, support and provide the patient with the available treatment 
A new Federal law, called the Genetic Information Nondiscrimination Act (GINA), generally 
makes it illegal for health insurance companies and group health plans to use genetic information in 
making decisions regarding your eligibility or premiums. GINA also makes it illegal for employers with 15 
or more employees to use your genetic information when making decisions regarding hiring, promoting, 
firing, or setting the terms of employment. This new Federal law does not protect you against genetic 
discrimination by companies that sell life, disability, or long-term care insurance. 
If we learn of any new information about study risks that could cause you to change your mind 
about continuing to participate your child in the study, we will notify you promptly. 
Benefits of participation in this research study: There is no benefit to participation in this 
research study other than possibly increased knowledge about your/your family’s disease. If a specific 
genetic disorder is identified, specific treatment may be available based on the information. 
None of the procedures you receive during this research study (research blood draws or 
genetic analysis) will be billed to you or your health insurance.  If you get a bill or believe your health 
insurance has been billed for something that is part of the study, notify a member of the research team.  
However, you or your insurer will be billed for all other usual care services, including routine surgery, 
blood draws for clinical/routine care, follow-up care, or testing done for clinical/routine purposes.  
You will not be paid for your child’s participation.  Although it is possible that your child’s 
biological samples may lead, in the future, to new inventions, discoveries or products that may be sold, 
licensed, or patented, there are currently no plans to share with you any money or other rewards that 
may result from the development of those new products.  
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If you believe that the research procedures have resulted in an injury to your child, 
immediately contact Dr. Vockley or a member of the Research Team (see first page). Emergency 
medical treatment for injuries solely and directly related to your child’s participation in this research 
study will be provided to your child by the hospitals of UPMC. Your insurance provider may be billed for 
the costs of this emergency treatment, but none of those costs will be charged directly to you. If his/her 
research-related injury requires medical care beyond this emergency treatment, you will be responsible 
for the costs of this follow-up care. At this time, there is no plan for any additional financial 
compensation. 
To protect your child’s privacy and maintain the confidentiality of information we obtain from 
your child and from his/her medical records, we will maintain all information about your child in a 
secure location. This research study will involve the recording of current and/or future identifiable 
medical information from your child’s hospital and/or other (e.g., physician office) records.  The 
information that will be recorded will be limited to information concerning your child’s genetic disorder.  
All paper records that could identify your child will be stored in locked file cabinets, and all electronic 
records will be stored in password-protected files. Your child’s identity on these records will be indicated 
by a case number rather than by his/her name, and the code linking his/her name to this number will be 
maintained separately with very limited access to research team members.  Although we will do 
everything in our power to protect your privacy and the confidentiality of your child’s records, just as 
with the use of his/her medical information for health care purposes, we cannot guarantee the 
confidentiality of your child’s research records, including information that we obtained from medical 
records. However, no third party, including relatives, personal physicians or insurance companies, or 
other researchers will have access to your child’s identifiable information, with one exception. 
Authorized representatives of the UPMC hospitals may have access to identifiable information only for 
the purpose of (1) filling orders made by the researchers for hospital and health care services (e.g., 
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laboratory tests) associated with the research study, (2) addressing correct payment for tests and 
procedures ordered by the researchers, and/or (3) for internal hospital operations (e.g., quality 
assurance).  Also, authorized representatives from the University of Pittsburgh Research Conduct and 
Compliance Office will have access to these files but only for the purpose of monitoring the conduct of 
the study.    
Your child’s doctor may also be involved as an investigator in this research study, but you are 
not under any obligation to give consent for your child to participate in any research study offered by 
your child’s doctor. Before agreeing to participate in this research study, or at any time thereafter, you 
may wish to discuss participation in this study with another health professional, to obtain a ‘second 
opinion’ about study participation.  You may also contact the University ‘Research Participant Advocate’ 
1-866-212-2668 for additional information.   
Your child’s participation in this research study is completely voluntary. Whether you 
participate/not participate in this research study will have no effect on your/ your child’s current or 
future relationship with the University of Pittsburgh, UPMC or its affiliated health care providers or 
health care insurance providers.  If you decide that your child no longer wishes to continue to 
participate after you have signed the consent form, you should contact Dr. Vockley or his colleagues. 
Your child’s blood samples and DNA will then be destroyed if they are not in the midst of being 
analyzed. You may also withdraw, at any time, your authorization to allow the research team to review 
your child’s medical records, but if you do so, your child will no longer be permitted to participate in this 
study.  Any information obtained from your child up to that point will, however, continue to be used by 
the research team.  Your decision to withdraw from this study will have no effect on your/ your child’s 
current or future relationship with the University of Pittsburgh or with UPMC or its affiliated health care 
providers or health care insurance providers. However if withdrawal takes place, no information 
regarding results will be returned to you and your child’s DNA sample will be destroyed so that no 
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additional future testing can be performed. Results from the sequencing study obtained prior to 
withdrawal will still be analyzed to the extent possible. 
 
VOLUNTARY CONSENT:  
 
All of the above has been explained to me and all my current questions are answered. I 
understand I am encouraged to ask questions and voice concerns or complaints about any aspect of this 
research during the course of it, and that those questions, concerns, or complaints will be answered by 
the researchers listed on the first page of the form. I understand that I may always request that my 
concerns be addressed by a listed investigator. I understand that I may contact the Human Subjects 
Protection Advocate of the IRB Office, University of Pittsburgh (1-866-212-2668) to discuss any issues; 
obtain information; offer input; or discuss situations in the event that the research team is not available. 
By signing this form, I agree to participate in this research study. A copy of this consent form will be 
given to me.  
 
 
____________________________________ 
Child/Subject Name 
 
“I understand that, as a minor (age less than 18 years), the above-named child is not permitted 
to participate in this research study without my consent.  Therefore, by signing this form, I give my 
consent for his/her participation in this research study.” 
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____________________________________                           __________________________ 
Parent’s Name (Print)                        Relationship to Participant  
 
 
____________________________________               __________________________ 
Parent’s Signature            Date 
 
CERTIFICATION of INFORMED CONSENT:  
 
I certify that I explained the nature and purpose of this research study to the above-named 
individual(s). I discussed the potential benefits and possible risks of study participation. Any questions 
the individual(s) have about this study have been answered, and we will always be available to address 
future issues that arise. I certify that no research component of this protocol was begun until after this 
consent form was signed. 
 
____________________________________ ______________________  
Printed Name of Person Obtaining Consent                                      Role in Research Study  
 
_____________________________________ ______________________  
Signature of Person Obtaining Consent                   Date 
 
 
 
 
 70 
ASSENT 
This research has been explained to me and I agree to participate. 
____________________________________ __________________________ 
Signature of Child-Subject Date 
VERIFICATION OF EXPLANATION: 
I certify that I have carefully explained the purpose and nature of this research study to the 
child-subject in age appropriate language.  He/she has had an opportunity to discuss it with me in detail. 
I have answered all his/her questions and he/she has provided affirmative agreement (i.e., assent) to 
participate in this study 
___________________________________ ___________________ 
Investigator’s Signature  Date 
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APPENDIX C 
COMPARISON OF COMMERCIALLY AVAILABLE WES 
Table 8 Comparison of Commercially Available WES by Laboratory 
Ambry Baylor GeneDx 
Platform: 
Illumina 
• WES on 3 relatives
• Trios can be
medically relevant
people in pedigree,
not just parents
and proband.
• Can call to
determine who in
pedigree they'd
want samples from
• Best scenario:
send as many
samples as
possible. Other
relations can be
coseg
• WES with CGH-SNP for
proband only
• Targeted Sanger sequencing
for parents on select variants
(AR cis vs trans, or to
determine de novo status
VUS)
• Specimens on family
members required
(both parents, in most
cases)
• Additional affected
and unaffected
members may be
required (call to
check)
Testing • Novel genes, VUS
• Initial eval: no
SIFT/PolyPhen,
remove SNPs
based on pop
frequency, degree
of conservation
• Collect samples on
all 1st degree
relatives
(parents/sibs) and
"affected" cousins
• Whole exome
proband- if
geno/pheno
• Novel genes, VUS
• Extended family members
can be tested for specific
mutations for a fee ($410 if
billing insurance, $385 if self-
pay)
• Moving towards trios but no
launch date yet
• Novel genes/VUS?
• Targeted testing of
family members for
specific mutations for
$350-500
• Can do other testing
in conjunction to
exome (full sequence
analysis and deletion
testing of mtGenome,
SNP array, whole
genome array CGH)
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correlation found, 
stop there. 
• If not, reflex to
exome 2 family
members, identify
mutation of
interest. Then do
coseg on other
family members
and confirm
utilizing sanger
sequencing on
exome candidates
Sample 
Collection 
• Blood sample: 6-
10cc in EDTA
(purple top) or
citric acetate
(yellow top) tube
per patient
• Saliva acceptable
for co seg
• Cultured skin
fibroblasts: 3 T25
cell flasks at 80%
confluence
• Kits provided by
lab
• Blood: 5cc (child) or 10cc
(adult) in EDTA (purple top)
tube
• Saliva acceptable for parents,
but blood preferred
• Cultured skin fibroblasts: 2
T25 flasks at 80-100%
confluence
• Kits provided by lab
• 5-10cc Blood, EDTA
tube.
• Specimens may be
refrigerated for 7
days prior to shipping
• High quality extracted
DNA can be accepted
(>15ug with minimum
concentration of
50ng/ul)
• Other tissue types –
call to discuss
Reporting • PROBAND ONLY
• Related to
phenotype
• Early-onset or
childhood onset
HGMD
genes/mutations
(no VUS)
• No formal report
on WES
candidates. Single
site testing is
available for an
additional $250
• VUS unrelated to
the phenotype will
not be interpreted
by lab but sheet
can be requested
by CHP
FOCUSED REPORT 
• Deleterious related to
phenotype
• VUS related to phenotype
• Mito related to phenotype
(>20% heteroplasmy, no VUS
or rare variants)
• Symptomatic XLR females
• Unrelated but medically
actionable- only
known/deleterious (i.e. adult
onset cancer [HNPCC,
BRCA1/2], cardiomyopathies
[DSP], coagulpoathies,
collagen mutations, G6PD,
undiagnosed secondary
conditions [NF1/2, Marfan]
relevant for parents)
• AR carrier status
• Pharmacogenetics (only
warfarin and Plavix
metabolism)
• CNV >1 Mb (will report <1 Mb
if known syndrome)
• Family can opt out of AR
carrier status and pharmaco
EXPANDED REPORT 
• PROBAND ONLY
• ONLY related to
phenotype
• 3 classes of
reporting:
• Cat.1: positive result,
known disease
association
• Cat.2: mutations
possibly representing
a diagnosis, felt to
be likely but lack of
definitive info to say
for sure
• Cat.3: candidate
genes, no human
disease
associations, based
on function,
expression, and
model organisms
• Identification of a
medically actionable
mutation will result in
call to ordering
physician to see if
they want the
information
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Table 8 continued
• Deleterious unrelated to
phenotype
• Mito <20% heteroplasmy
• Includes: disease causing,
VUS, deleterious w/ no
known assoc with human
• Asymptomatic XLR females
• heterozygous VUS assoc with
AR d/o will only be reported
only if deleterious or 2nd VUS
in the same gene is detected
(examples so far: 
hereditary 
arrhythmia, an 
anemia unsure if was 
caught on NBS) 
• Otherwise, not
reporting unrelated
secondary
diagnoses
Not 
Reported 
• AR carrier status,
predisposition to
late onset disorder
or cancer risk
• Exception:
childhood cancer
(VHL/NF…), with
some exceptions,
and even then only
HGMD genes are
reported (no VUS)
• drug metabolism or
common disease
• Adult onset dementia
syndromes with no treatment
will not be reported in focused
or expanded. Reportable but
needs to be specifically
requested. May report if
suspicious hit that is "not
certain but likely to be
involved w/patient's disease",
but would discuss w/doctor
• no other loci/conditions
blacked out
• variations in genes
unrelated to
phenotype
• includes: benign
variants, common
diseases, carrier
status, and adult
onset
Turnaround 
Time 
• CDE: 28 weeks • 15 weeks
• Expanded report can be
ordered (with parent consent)
up to 6 months afterwards for
free, with 4 week turnaround
• 12-16 weeks
Limitations • CNV, large 
rearrangements, 
tri-allelic, mito 
genome, 
epigenetic, 
trinucleotide repeat 
expansion, XLR 
females 
• Large rearrangements, tri-
allelic, epigenetic,
trinucleotide repeat
expansion,
• CNV, large
rearrangements, tri-
allelic, mito genome,
epigenetic,
trinucleotide repeat
expansion, XLR
females
Follow-up 
VUS 
• Review of VUS are
the responsibility of
ordering
physician/counselo
r
• Review of VUS are the
responsibility of ordering
physician/counselor
• Review of VUS are
the responsibility of
ordering
physician/counselor
Price • $7900 for trio • $7000 for proband • Proband only - $5000
• 2 parents and
proband - $9000
• Each additional family
member - $2500
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Table 8 continued
Insurance • pre-auth service
provided- >$300
OOP=family
notified
• pre-auth service provided • Pre-auth services
provided, credit card
info required at time
of sample
submission
• OOP costs will be
limited to $1000 per
trio (except in FL and
CO)
• Does not accept
Medicare, Medicaid,
or Tricare
Patented 
Genes 
• report gene( not
specific mutation)
to Athena/Myriad
and CHP
simultaneously-
CHP pursue seq
w/ Athena/Myriad
• report very specific
mutation/gene to CHP
simultaneously- suggest
pursue testing by licensed
lab
• Will report results,
including specific
mutation, just not
confirm with Sanger
seq
Stored Data • Keep data for two 
years 
• DNA is held until
the proband is 18,
or for 1 year if
proband >18 at
time of testing
• If patient <18 yr,
suggest re-
sequencing
• Keep data for 10 years
• Can re-interpret existing data
after 1 year, for a small fee
(amount currently
undetermined)
• Will eventually (after enough
years/improved tech)
recommend resequencing
(like with arrays)
• Full sequence data
held for at least 1 yr
• Variant calls held
indefinitely
• Offers annual re-
analysis (first one at
no charge) or re-eval
of other ones (cost
not yet determined
for subsequent re-
analysis)
Cancellation 
of Testing 
• If sequencing has
not started,
extracted DNA is
held for 1 year
unless instructions
to do otherwise.
• If sequencing has
started, dealt with
on case-by-case
basis depending
on where in the
process it is.
• If sequencing has not
started, purple-top tubes will
be discarded. Extracted DNA
will be held and possibly
used for research under
CLIA guidelines.
• If sequencing has started, a
report will still be generated
• If sequencing has
started, can request
that the data not be
analyzed, but sample
will still be
sequenced and
patient billed
• Have5 business days
to cancel before
sequencing starts
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Table 8 continued
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